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ABSTRACT
The investigation of a biological system can be probed in multiple fashions
to improve our understanding of how they work. The work presented in this
dissertation demonstrates how my work utilizes synthesis and spectroscopy to
probe biological systems and gain a deeper understanding of cellular processes.
My abilities as both an organic and analytical chemist are displayed throughout
the projects that I have worked on throughout my graduate studies. Real
advances have been made in the probed biological systems, allowing future
researchers to take a more targeted approach from the chemical knowledge
presented.
Chapter 1 will focus on the degradation of dichloromethane in two
members of the Peptococcaceae family. Initial isotope analysis of the
degradation of DCM anaerobically suggests that each bacterium have a unique
mechanism to convert DCM to non-toxic byproducts. An NMR analysis study
using

13

C-DCM is applied to both pure culture Dehalobacterium formicoaceticum

and the mixed culture consortium RM containing DCM degrader Candidatus
Dichloromethanomonas

elyunquensis

to

observe

the

degradation

and

subsequently perform a pathway analysis.
Chapter 2 is a study on the induction of diabetes that is associated with
the prolonged treatment of inflammation with glucocorticoids. These drugs have
wide ranging applications due to their global anti-inflammatory properties
although they tend to limit the secretion of insulin in β [beta]-cells located in the
pancreas. To gain a better understanding of this effect a library of glucocorticoids
containing both steroidal and non-steroidal scaffolds were synthesized,
characterized, computationally modeled, and tested in-vitro as potential antiinflammatory drugs with candidates displaying little to no effect on insulin
production.
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INTRODUCTION

1

Human life has transformed drastically since the events that led to the scientific
revolution and the emergence of modern science. During the time science was
divided into disciplines of astronomy, biology, mathematics, physics and
chemistry. The initial research of these disciplines changed the way society
viewed nature, disease and life in general. Scientific discoveries at the time had
monumental impacts on life in general but maybe most importantly in diseases
and human anatomy. Monumental scientific discoveries can still effect societal
views todays in a positive matter. The work presented herein show investigations
into biological systems using very different interdisciplinary approaches. They
share a common investigation into problems that were created by humans. The
first chapter will detail the approach taken to solving the problematic
bioremediation of dichloromethane in our ground and drinking water supplies.
The second chapter will entail an investigation into solving the harmful sideeffects caused by the long term use of glucocorticoids. The experiment will
provide information into the structure-activity relationship the glucocorticoid
ligand-glucocorticoid receptor play in the design of a dissociated steroid, one that
can separate the anti-inflammatory properties from the harmful side-effects.
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CHAPTER I
NMR ANALYSIS OF DICHLOROMETHANE DEGRADATION
PATHWAYS BY TWO MEMBERS OF PEPTOCOCCACEAE

3

Contributions:
This chapter contains material that is to be part of future publications by:

Alexander R. Fisch, Gao Chen, Frank Loeffler, Shawn R. Campagna

Alexander R. Fisch ran the NMR experiments and analyzed the data. GC grew
the bacterial cultures, assisted with analysis of the data and ran isotope analysis.
FL and SRC provided funding and conceptualization for this project.
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1.1 Abstract
Dichloromethane (DCM) is a frequently used industrial solvent that has been
found to be a probable human carcinogen and frequently found as a contaminant
in groundwater. It is toxic to the ecosystem and its volatility causes stratospheric
ozone layer depletion. The degradation of DCM aerobically is done by harboring
glutathione-dependent DCM dehalogenases, although build up DCM in
groundwater exists in oxygen deprived environments and little is known about
anaerobic DCM degradation. Two members of the Peptococcaceae family were
found to degrade DCM anaerobically. Initial isotope analysis of the degradation
of DCM by the two bacteria suggests they each have a unique mechanism to
convert DCM to non-toxic byproducts. An NMR analysis using

13

C-DCM is

applied to both pure culture Dehalobacterium formicoaceticum and the mixed
culture

consortium

RM

containing

DCM

degrader

Candidatus

Dichloromethanomonas elyunquensis.

1.2 Introduction
1.2.1 Chlorinated solvents
Chlorinated solvents were first discovered over 100 years ago and were
commonly used by the 1940’s. Since that time, chlorinated solvents and their
degradation products have become the most extensive organic contaminant
found in groundwater of the United States.1 Chlorinated solvents are used across
an array of industrial and commercial applications as well as many consumer and
household products. The properties of the solvents have resulted in many uses.
Chlorinated solvents are roughly all nonflammable and noncorrosive, in addition
to being exceptional degreasing agents. The degreasing properties of the
solvents are used to clean everything from clothing to electronics to large
manufacturing equipment. Dichloromethane (DCM), trichloroethane (TCE), 1,1,1trichloroethane (TCA), and carbon tetrachloride (CT) are some of the most
commonly used chlorinated solvents.1 Once these solvents are released into the
5

environment, they have the tendency for widespread contamination due to their
physical and chemical properties.2 A number of treatment technologies have
emerged the one to prove most successful thus far involve the use of biological
degradation. Research in the 1980’s provided the first documentation of common
chlorinated

solvents

TCE,

TCA,

and

CT

could

be

biodegraded

by

microorganisms that are present in groundwater and soil.3-6 The bioremediation
industry at the time did not have a complete understanding of the microbiological
process and what individual bacteria where involved. 7 It was not until the early
1990’s that bacteria were being discovered that were degrading specific
chlorinated solvents.8
1.2.2 Dichloromethane in groundwater
Dichloromethane is one of the smallest chlorinated solvents found as a pollutant
in groundwater and soil. It was first synthesized in 1840 by V. Regnault who was
able to use light to chlorinate methyl chloride.9 It is a colorless, neutral, highly
volatile liquid with a hint of a sweet smell. DCM is nearly nonflammable in the air,
it only becomes flammable under a limited number of oxygen-nitrogen
combinations.9 That makes DCM unique when compared to chlorinated solvents
as it’s the only one with a low boiling point and nonflammable. The vast majority
of the DCM in the environment is due to anthropogenic activity, although small
amounts are produced naturally in the oceans, soils and wetlands or through
volcanic activity and emissions.1 DCM is used as an industrial solvent, synthetic
intermediate,

dry-cleaning

solvent,

degreasing

agent

in

electronics,

manufacturing and industrial machine maintenance.10 Due to its vast use,
accidental releases and ill-advised disposal practices DCM can be found in large
concentrations near industrial areas.11 In residential areas it is commonly
detected in the soil, groundwater and drinking water wells in the United States
(U.S).12 DCM was found in concentrations from 0.02 to 100 μg L -1 (ppb) across
groundwater in the U.S. The Environmental Protection Agency (EPA) registers
DCM as a priority contaminant and is has listed the solvent as a probable human
6

carcinogen and can cause kidney and liver damage.11, 13 In addition to polluting
the ecosystem, it can cause stratospheric ozone destruction and is a potent
greenhouse gas.14 The released DCM into the environment causes the solvent to
migrate through the soil and assembles as a dense liquid that doesn’t dissolve
into the water and sits as a layer at the bottom of polluted aquifers. 15 In situ
bioremediation efforts to detoxify the contaminated sites have proven efficient
and at a relatively low cost.
1.2.3 Degradation of dichloromethane
The degradation of DCM under nitrate-reducing and oxic conditions is well
documented and has been studied in detail.16, 17 The degradation is mediated by
facultative bacteria and aerobes containing glutathione-dependent DCM
dehalogenases that leads to complete detoxification to carbon dioxide (CO 2) and
inorganic chloride (Cl-).6,

18, 19

The aerobic bacterium Acinetobacter sp. was

isolated from activated sludge that grows on DCM as the only source of organic
carbon and energy under nitrate-reducing conditions.20 Methylotrophic bacterial
strains Hyphomicrobium, Methylobacterium, Methylopila, Methylophilus and
Methylorhabdus spp. were all found to degrade DCM under aerobic and nitratereducing conditions.18,

21

The main complication with the application of aerobic

bacteria for bioremediation of groundwater is the low dissolved oxygen
concentration found. Therefore, bioremediation efforts have turned to anaerobic
biodegradation as a preferred strategy for clean-up of polluted aquifers.
The anaerobic degradation of DCM under anoxic conditions is far less
understood than aerobic degradation. Unlike bacteria that degrade DCM
aerobically through direct hydrogenolysis (i.e. reductive dechlorination), rather
DCM is channeled into the Wood-Ljungdahl pathway or reductive acetyl-CoA
pathway broken into hydrocarbons and inorganic chloride. 22 Dehalobacterium
formicoaceticum, affiliated with the Peptococcaceae family is the only pure
culture identified to metabolize DCM via a fermentative pathway producing
formate and acetate in a molar ratio 2:1 respectively (Figure 1).8, 23
7

Figure 1: Degradation byproduct of DCM metabolism by D.
formicoaceticum

The second bacterial strain to be found to degrade DCM under anoxic conditions
was discovered within a mixed culture harboring organism affiliated with the
Peptococcaceae family, e.g., Dehalobacter sp. and/or Dehalobacterium sp24. The
mixed culture, consortium RM was derived from pristine Rio Mameyes River
sediment collected close to the El Yunque National Forest in Puerto Rico. 25 The
DCM-degrading bacterium in the mixed culture was identified as Candidatus
Dichloromethanomonas elyunquensis, leading to a new genus and species in the
Peptococcaceae family which metabolizes DCM to acetate, H2, CO2 and Cl.(Figure

2)26-29

The

two

organisms

D.

formicoaceticum

and

Ca.

Dichloromethanomonas elyunquensis appear to use similar mechanisms for the
degradation of DCM under anoxic conditions through fermentation pathways.8, 25,
29

Past studies on D. formicoaceticum and Ca. Dichloromethanomonas

elyunquensis proposed a degradation funneling DCM into the Wood-Ljungdahl
pathway (i.e., reductive acetyl-CoA pathway) (Figure 3)

Figure 2: Degradation byproducts of DCM metabolism by mixed culture
Consortium RM

8

Figure 3: Proposed degradation of dichloromethane in D. formicoaceticum

9

The proposed degradation of DCM begins with the removal of the chlorine as
hydrochloric acid. The carbon from DCM will then find its way onto methylene
tetrahydrofolate (CH2=THF) where it can be inserted into the Wood-Ljungdahl
Pathway. 3 equivalents methylene tetrahydrofolate molecules enter the pathway
and two thirds is oxidized to formate forming formyl tetrahydrofolate (CHO-FH4).
The other third of methylene tetrahydrofolate is reduced to acetate with the
addition of carbon dioxide.
Past experiments of D. formicoaceticum and Ca. Dichloromethanomonas
elyunquensis have been able to determine the byproducts resulted from DCM
fermentation although the removal of the chlorine mechanism has not been
resolved. It remains a challenging task to study the bacteria due to the anoxic
conditions in which the bacteria are grown and studied. To determine the
mechanism of the removal of chlorine and subsequent intermediates it is
imperative that the system is observed in a closed system to control the growth
environment.
Researchers are challenged with the task of providing concrete evidence that
bioremediation will lead to detoxification. Decreasing toxic pollutants or
contaminants concentrations are not always an absolute measure of the
bioremediation effort due to processes like adsorption or dilution being factors
behind the observation. The discovery of the mechanism for the removal of
chlorine can aid in the optimization of remedial strategies.
1.2.4 Targeted NMR spectroscopy
Nuclear Magnetic Resonance (NMR) spectroscopy offers techniques that could
possibly elucidate the pathway in the degradation of DCM in D. formicoaceticum
and Ca. Dichloromethanomonas elyunquensis. NMR does not have near the
sensitivity as mass spectrometry, although it does have its advantages through
its ability to quantify metabolites in a biological system with little need for sample
preparation or fractionation.30, 31 The minimal amount of preparation needed for
NMR leads to an observation window into the changing metabolome in vivo. The
10

use of stable isotope labels can be used to study the mechanisms and dynamics
of metabolite transformations. Therefore, infusion of a

13

C-labeled substrate, like

13

C-DCM feed to the bacteria can allow for the detection of all

13

C-metabolites

that are the degradation products of the DCM fermentation.
There are multiple NMR experiments that can be used to elucidate pathway
mechanisms. One or two-dimensional methods can be used as well as detecting
specific nuclei in a biosystem. One dimensional (1D) 1H-NMR is commonly used
due to the abundance of hydrogen in a biosystem, the sensitivity of the
experiment and the ability to quantify metabolites. The experiment has answered
many relevant questions in metabolomics using standard 1H-NMR databases to
fit experimental spectra to identification and quantification of metabolites. 32-35 13CNMR has a larger spectral range, typically over 220 ppm compared to the typical
10 ppm in 1H-NMR. This aids in the spectral resolution if there are many signals
in the 1H-NMR that begin to overlap.

13

C-NMR does indeed suffer from a low

sensitivity due its natural abundance (1.1%), which is more than 8 times less
than 1H-NMR. However, the low natural abundance of

13

C can be turned into an

advantage using stable isotope labels. Isotopically labeled

13

C has seen many

applications in NMR spectroscopy for multiple biosystems including elucidating
the human brain amino acid labeling with

13

C-glucose. 36-39 Two dimensional (2D)

NMR methods are used for coupling nuclei for the unambiguous identification of
metabolites in a sample.40 Common methods used today are 1H-1H COSY
(correlated spectroscopy), 1H-1H TOCSY (total correlation spectroscopy), 1H-13C
HSQC

(heteronuclear

single-quantum

correlation),

and

1

H-13C

HSQC

(heteronuclear single quantum coherence or heteronuclear single quantum
correlation experiment). There are software’s that can be used to match
experimental spectra for metabolite or compound identification. 41
Stable isotope tracing is without a doubt the most useful technique when
elucidating mechanisms or transformations within a biosystem. The isotope can
be traced through 1D

13

C-NMR due to its increased sensitivity but can also be

traced in 1H-NMR using an indirect 1H-[13C] NMR method. This method is used to
11

detect protons that are directly attached to a

13

C nuclei. The larger gyromagnetic

ratio of protons is the reason for this effect. With the 1H-NMR spectrum, signals
can be detected for binding to both

12

C and

13

C nuclei leading to the ability to

calculate the in vivo enrichment of labeled metabolites.
1.2.5 Targeted mass spectrometry
As previously mentioned mass spectrometry is another technique commonly
used to probe metabolic pathways typically used in tandem with separation
techniques that precede the detection. Liquid chromatography is by far the most
used separation method in biological systems. Liquid chromatography – high
resolution mass spectrometry (LC-HRMS) can detect thousands of metabolites at
concentrations in the nano molar range with very good resolution. 42, 43 NMR and
MS used together for the study of a pathway because of the different answers
each technique can solve. Using a stable labeled isotope with MS can measure
multiple isotopes of the same molecule simultaneously. NMR has to the ability to
measure multiple isotope species of the same molecule although the more
labeling occurring in the sample and the spectra will get very complex and signal
begin to overlap, decreasing the resolution of individual peaks. Targeted MS
studies using a stable isotope label have been essential to probing biological
pathways and discovery significant molecular markers.44-47

1.3 Material and Methods
1.3.1 Cultures, cultivation conditions and experimental setup
Chemicals
DCM (purity>99.95%) was purchased from Acros Organics (Thermo Fisher
Scientific, Fair Lawn, NJ, USA).

13

C-labeled DCM (99 atom %

13

C) was

purchased from Sigma-Aldrich (St. Louis, MO, USA). HPLC grade propanol,
pyridine, propyl chloroformate (PCF), and hexane were purchased from SigmaAldrich (St. Louis, MO, USA). All other chemicals used were analytical reagent
grade or higher, unless otherwise specified.
12

Microorganisms and cultivation
Culture RM, harboring DCM-degrading Ca Dichloromethanomonas elyunquensis,
was enriched from freshwater sediments.25 After establishing the enrichment
culture, culture RM was maintained in the laboratory as active cultures by
repeated transfers in fresh medium with DCM as the sole substrate. D.
formicoaceticum was obtained from American Type Culture Collection (ATCC
700118). Both D. formicoaceticum and culture RM were cultivated in
bicarbonate-buffered (30 mM, pH 7.3) anoxic basal salt medium and the routine
cultivation was performed as described previously.29, 48

Analytical methods
DCM and methane were measured by manual headspace injections (0.1 ml) into
an Agilent 7890A gas chromatograph (GC) (Santa Clara, CA, USA) equipped
with a DB-624 column (60 m length, 0.32 mm i.d., 1.8 mm film thickness) and a
flame ionization detector (FID). The GC inlet was maintained at 200 °C, the GC
oven temperature was kept at 60 °C for 2 min followed by an increase to 200 °C
at a ramping rate of 25 °C min–1, and the FID detector was operated at 280 °C.
Acetate and formate were measured using an Agilent 1200 series highperformance liquid chromatography (HPLC) system equipped with an Aminex
HPX-87H column (Bio-Rad, Hercules, CA, USA) and a UV detector set to 210
nm. The separation occurred at a column temperature of 30 °C, and the eluent (4
mM H2SO4) was delivered isocratically at a rate of 0.6 ml min–1 for 25 min.
For acetate analysis, a volume of 800 µl culture samples were taken using N 2flushed syringes and centrifuged to remove cells. The derivatization of acetate to
propyl acetate was performed as described previously. 34 In brief, 800 µl sample
was mixed with 500 µl of propanol/pyridine mixture solvent (v/v = 3 : 2) in a glass
vial and 100 µl of PCF was subsequently added. The resulting mixture was
vortexed briefly and the derivatization reaction proceeded under ultrasonication
for 1 min. After derivatization, the derivatives were extracted with 300 µl of
hexane, which was undergone GC-MS analysis. GC-MS analysis was performed
13

using an Agilent 7890A gas chromatograph (Santa Clara, CA, USA) equipped
with a DB-624 column (60 m length, 0.32 mm i.d., 1.8 mm film thickness) and an
Agilent 5975C inert XL MSD with a Triple-axis detector (Santa Clara, CA, USA).
The GC inlet was maintained at 200 °C, and the GC oven temperature was kept
at 60 °C for 2 min followed by an increase to 90 °C at a ramping rate of 5 °C min–
1

and then another increase to 200 °C at a rate of 25 °C min –1. All samples were

stored at 4 °C in the dark until mass spectrometry and NMR analysis.
1.3.2 NMR experimental setup of Ca. Dichloromethanomonas elyunquensis
All the compounds used are commercially available and were used without
further purification. The NMR sample was prepared in a glove box under argon
gas. The NMR tube used was a custom order from New Era Enterprises, Inc
featuring an outer 5-mm diameter tube with a septum screw tip and a separate
inner tube with cap.

13

C-DCM was fed to the bacterial culture directly prior to

insertion into NMR tube. The bacteria culture was transferred into the outer NMR
tube followed by insertion of inner NMR tube containing D2O with internal
standard 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS). All NMR spectra was
acquired using an Inverse probe on a liquid state Varian VNMRS 600 MHz. 1HNMR was acquired with a pulse sequence that included a pre-saturation of the
H2O signal. For all 2D spectra acquired (1H-13C) HSQC and (1H-13C) HMBC a
pulse sequence was used for the saturation of the H 2O signal. All processing of
the NMR data was done using MestReNova NMR software. All spectra were fit
and normalized to the internal standard peak at 0 ppm.
1.3.3 NMR experimental setup of D. formicoaceticum
All the compounds used are commercially available and were used without
further purification.

13

C-DCM was fed to the pure bacterial culture and nearly

completely metabolized prior to extraction. The NMR tube used was a custom
order from New Era Enterprises, Inc featuring an outer 5-mm diameter tube with
a septum screw tip and a separate inner tube with cap. The bacteria culture was
14

transferred into the outer NMR tube followed by insertion of inner NMR tube
containing D2O with internal standard DSS. All NMR spectra was acquired using
an Inverse probe on a liquid state Varian VNMRS 600 MHz. 1H-NMR was
acquired with a pulse sequence that included a pre-saturation of the H2O signal.
For all 2D spectra acquired (1H-13C) HSQC and (1H-13C) HMBC a pulse
sequence was used for the saturation of the H2O signal. All processing of the
NMR data was done using MestReNova NMR software. All spectra were fit and
normalized to the internal standard peak at 0 ppm.
1.3.4 Extraction of D. formicoaceticum fed 13C-DCM for metabolomics
analysis
The untargeted UPLC-HRMS study of D. formicoaceticum extracted culture fed
isotopically labeled

13

C-DCM for the detection and identification of

13

C labeled

amino acids. The pure culture of D. formicoaceticum previously mentioned was
passed through a filter for cell collection and kept frozen on dry ice until
extraction. The frozen filter was then placed in an empty petri dish and 1.3 mL of
cooled extraction solvent was placed on top of the filter. The extraction solvent
was made up of 40:40:20 ACN: MeOH: H2O with 1% formic acid. The filter was
left for and extraction period of 15 minutes at -20 °C. The filter was then removed
from the petri dish and washed with extraction solvent. The filtrate was then
placed in an Eppendorf tube and centrifuged for 5 minutes. The resulting
supernatant was transferred to a 1-dram vial and the contents dried under
nitrogen. At 4 °C, the remaining solid biomass was resuspended in 300 μL of prechilled MiliQ water and transferred to an autosampler vial.
1.3.5 Untargeted metabolomics using UPLC-HRMS of D. formicoaceticum
extraction
The autosampler vial was placed on an autosampler tray at 4°C. 10 μL of the
aliquot was injected through a Synergi 2.5-micron reverse Synergi 2.5-micron
reverse phase Hydro-RP 100, with a 100 x 2.00 mm LC column (Phenomenex,
15

Torrance, CA) kept at 25 ˚C. The eluent was imported into the MS via an
electrospray ionization source conjoined to an Exactive™ Plus Orbitrap Mass
Spectrometer (Thermo Scientific, Waltham, MA) through a 0.1 mm internal
diameter fused silica capillary tube. The mass spectrometer was run in full scan
mode with positive ionization mode with a window from 85 – 1000 m/z. with a
method adapted from Lu et al., 2010

49

. The samples were run with a spray

voltage was 3 kV. The nitrogen sheath gas was set to a flow rate of 10 psi with a
capillary temperature of 320˚C. AGC (acquisition gain control) target was set to
3e6. The samples were analyzed with a resolution of 140,000 and a scan window
of 85 to 800 m/z for from 0 to 9 minutes and 110 to 1000 m/z from 9 to 25
minutes. Solvent A consisted of 97:3 water: methanol, 10 mM tributylamine, and
15 mM acetic acid. Solvent B was methanol. The gradient from 0 to 5 minutes is
0% B, from 5 to 13 minutes is 20% B, from 13 to 15.5 minutes is 55% B, from
15.5 to 19 minutes is 95% B, and from 19 to 25 minutes is 0% B with a flow rate
of 200 µL/min.
Files generated by Xcaliber (RAW) were converted to the open-source mzML
50

format

package

via the open-source msconvert software as part of the ProteoWizard
51

. Maven (mzroll) software, Princeton University

52, 53

was used to

automatically correct the total ion chromatograms based on the retention times
for each sample.

53, 54

Metabolites were manually identified and integrated using

known masses (± 5 ppm mass tolerance) and retention times ( ≤ 1.5 min).
Unknown peaks were automatically selected via Maven's automated peak
detection algorithms. Isotopic ratios were calculated using Excel 2010.

1.4 Results
1.4.1 Byproduct analysis of consortium RM in vivo culture
The

13

C-labeled DCM that was fed to the mixed bacterial culture was degraded

completely over a span of 22 days. The degradation was primarily tracked by 1HNMR as it is the most sensitive technique and took the least amount of time to
16

observe the

13

C-DCM signals. The analysis of the byproducts of the

13

C-DCM

degradation was complicated by consortium RM containing numerous bacterial
strains within. It could not be concluded if the byproducts observed were the
direct degradation product of the DCM degrader in the mixed culture Candidatus
Dichloromethanomonas elyunquensis or another bacterium in the mixture. The
prominent byproducts observed were carbon dioxide and acetate. Methanol and
methane observed but in small quantities. (Figure 4, Figure 5)
The presence of the methane can be explained due to the consortium RM culture
previously found to contain methanogens or methane gas producing bacteria. 28
The determination of the byproducts produced was done with the help of arrays
made from the NMR spectra acquired. The individual peaks were identified
searching NMR chemical shift databases. (Figure 6, Figure 7)
The 13C-DCM proton signal is split into a doublet when observing the signal in the
1

H-NMR spectra due to heteronuclear scalar coupling. A non-isotopically labeled

carbon will produce 1H-NMR signals with small sidebands appearing in the most
intense signals in a spectrum. These sidebands are due to the 1.1% naturally
abundant 13C nuclei. All of the peaks identified in the spectra where aided by 2-D
(1H-13C) HSQC NMR for peak confirmation. (Appendix 1.6.1)
1.4.2 Isotope analysis of consortium RM
The isotope analysis of the

13

C was done using both 1H and

13

C-NMR.

13

C-NMR

spectra taken over the 22 days (Figure 6) displaying the DCM singlet at 53 ppm
reducing in intensity. The peaks at 160 ppm and 124 ppm both grew in intensity.
The carbonate peak was expected as it makes up part of the buffered aqueous
buffer. The peak at 124 ppm was identified as carbon dioxide after 2D
experiments (1H-13C) HSQC, (1H-13C) HMBC, (13C-13C) DEPT. (Appendix 1.6.1)
From the

13

C-NMR data it is clear to assume the

13

C-DCM carbon has ended up

on carbon dioxide. The carbon dioxide is in equilibrium with the carbonate within
the closed system therefore it’s assumed the label was exchanged onto the
carbonate molecule as well. The 1H-NMR spectra tracked the doublet signal
17

Figure 4: 1H-NMR analysis of byproducts identified in mixed culture Consortium RM after feeding

13

C-DCM
18

Figure 5: 13C-NMR analysis of byproducts identified in mixed culture Consortium RM after feeding

13

C-DCM
19

Figure 6: 1H-NMR stacked analysis of mixed culture Consortium RM after feeding

13

C-DCM

20

Figure 7: 13C-NMR stacked analysis of mixed culture Consortium RM after feeding 13C-DCM
21

produced by 13C-DCM at 5.3 ppm and 5.5 ppm through its degradation or drop in
intensity over time. The absence of a doublet produced in the byproducts
detected was further evidence the labeled

13

C ended up on carbon dioxide.

1.4.3 Pathway analysis of consortium RM
The NMR spectra concluded through isotope analysis that the
isotopically labeled

13

C label from the

13

C-DCM fed to the mixed culture consortium RM resulted in

13

C-CO2. Previous literature suggested that the DCM was metabolized or

fermented through the Wood-Ljundahl pathway (i.e. reductive acetyl-CoA
pathway) although the exact mechanics of how the molecule enters the pathway
is not understood. Figure 8 summarizes the tracking of the labeled 13C-DCM as it
is metabolism in the Wood-Ljundahl pathway. The

13

C-DCM enters the pathway

and the chlorines are removed as HCl, the remaining CH2 is bound to
tetrahydrofolate (FH4) forming (CH2= FH4). The CH2= FH4 molecule is found only
to take the formate branch. It was understood that the CH 2= FH4 entered the
pathway and two-thirds of it is oxidized to formate and one-third reduced to form
acetate in combination with CO2.24 Isotope analysis of this experiment proved
otherwise as no labeled acetate molecule (13C-CH3COOH) was found and only
13

C-CO2 was detected. The intermediates in the pathway were not detected as

their turnover rate or concentration was under the limit of detection. Future
experiments on the mixed culture Consortium RM will be aimed at slowing the
metabolism down by scanning the culture using variable temperature NMR to
cool down the probe and sample while scanning. The scanning will focus on the
acquisition of data aimed at detecting only the bonds containing the

13

C-1H

signal, while dampening the signal produced by the naturally occurring

12

C-1H

signals.
1.4.4 Byproduct analysis of pure culture D. formicoaceticum
The analysis of the culture containing D. formicoaceticum was analyzed using
multiple NMR experiments for detection and identification of metabolites. The
22

Figure 8: Isotopic tracking of 13C carbon label from 13C-DCM fed to
consortium RM

23

13

culture had nearly consumed all

C-DCM prior to analysis and could only be

detected with long scan times. The byproducts detected in the culture were
methanol, acetate, carbonate and glycine with certainty in the 1H-NMR and

13

C-

NMR. (Figure 9)
The peaks were identified with the aid of 2D (1H-13C) HSQC. (Appendix 1.6.3)
1.4.5 Isotope analysis of pure culture D. formicoaceticum
The isotope analysis of the degradation of the
both 1H-NMR and

13

C-DCM signal was tracked using

13

C-NMR. Due to the heteronuclear scalar coupling effect, all

1

H signals that are bound to a

13

C nucleus will appear as a doublet in the 1H-

NMR spectrum. The metabolites that were identified containing an isotope label
were acetate, methanol and glycine.

13

C-NMR was able to identify that the

carbon labeled on the acetate was indeed the methyl carbon and not the
carbonyl carbon due to the intensity of the peak at 21ppm. Confirmation of the
labeled metabolites identified was done using a 1D gradient (1H-13C) HSQC that
was modified to delete the coupling of the signals in the t2 channel. (Figure 11)
The resulting spectra displayed bonds generated from an isotopically labeled
carbon originating from

13

C-DCM degradation. (Figure 12) The labeled peaks

that were detected in the spectra were DCM, glycine, methanol and acetate. DSS
was also detected but only due to its high concentration in the internal standard
when compared to the compounds detected in the culture. The DSS signals
detected are the 1.1% naturally abundant

13

C carbon produced by the molecule.

The methanol was an expected peak as it was seen in the Consortium RM
culture and detected in past literature.23
In addition to the labeled acetate detected, unlabeled acetate was detected in the
1

H-NMR scans. The ratio of labeled acetate/ unlabeled acetate detected was

1.73. The peak at 2.20 ppm was identified as the unlabeled acetate anion, with
labeled acetate anion side bands at 2.30 and 2.10 ppm. The isotopic ratio of
labeled/unlabeled was found to be 1.73 as well leading to the conclusion that is it
exchanged/ in equilibrium within the culture. The remaining isotopic ratios of
24

Figure 9: 1H-NMR analysis of byproducts identified in pure culture D. formicoaceticum after feeding 13CDCM
25

Figure 10: 13C-NMR analysis of byproducts identified in pure culture D. formicoaceticum after feeding 13CDCM

26

Figure 11: Pulse sequence diagram of 1D gHSQC experiment

27

Figure 12: NMR spectra of 1H-gHSQC (orange) superimposed on 1H-NMR (grey)
28

metabolites identified was found to be methanol 1.34 labeled/unlabeled and
glycine 2.0 labeled/unlabeled.
1.4.6 Pathway analysis of pure culture D. formicoaceticum
The

pathway

analysis

for

the

metabolism

of

DCM

by

the

Dehalobacterium formicoaceticum was first published in 1996.

bacteria
8

It was

hypothesized the DCM would be metabolized into acetate and formate. The
detection of only labeled acetate in the experiments conducted and the absence
of labeled formate/ carbon dioxide detected leads to believe that only the acetate
branch of the wood ljundahl pathway is “activated” during the degradation of
DCM by Dehalobacterium formicoaceticum. (Figure 13) The experiment
suggests that DCM is degraded via the Wood-Ljungdahl pathway (i.e. reductive
acetyl-CoA pathway) under anoxic conditions beginning with DCM entering the
pathway and subsequent removal of the chlorines occur. The remaining CH 2 is
combined with tetrahydrofolate to form methylene tetrahydrofolate (CH2=FH4).
CH2=FH4 will then get reduced into methyl tetrahydrofolate (CH3-FH4). The
methyl tetrahydrofolate can be combined with iron-sulfur proton (CoFeSP)
forming methyl-COFeSP (CH3-CO-E). The complex can be combined with
carbon monoxide to produce an acetate group and acetyl-COA. The degradation
of DCM by D. formicoaceticum is evidently not only restricted to the carbon
fixating pathways alone as labeled glycine and methanol were detected. Glycine
is related to the Wood-Ljundahl pathway playing parts in purine biosynthesis, B 12
biosynthesis and menaquinone biosynthesis. The labeled glycine suggests an
entry point for DCM integration into the Wood-Ljungdahl at the methylene
tetrahydrofolate (CH2=FH4). (Figure 14) The labeling of methanol remains
misunderstood how it relates to the degradation of DCM. The observation
suggests that methanol is formed by a side reaction that is coupled to DCM
degradation in some fashion.
Further evidence that dichloromethane was used as the primary growth substrate
by D. formicoaceticum was observed during the metabolomic study done on the
29

Figure 13: Pathway analysis of pure culture D. formicoaceticum fed
isotopically labeled 13C-DCM

30

Figure 14: Proposed pathway for the degradation of DCM in D.
formicoaceticum expanding from carbon fixating pathway
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extracted bacterial culture. 22 amino acids were detected containing a labeled
carbon with most containing multiple carbon labels. All amino acids that where
found incorporating the carbon label from the degradation of

13

C-DCM are found

in Appendix 1.6.4. The detection of multiple labeled amino acids signifies that D.
formicoaceticum is using degraded 13C-DCM for the production of energy and the
storage of biomass.

1.5 Conclusion
The targeted NMR analysis of DCM degraders in the Peptococcaceae family,
Dehalobacterium formicoaceticum and consortium RM comprising Candidatus
Dichloromethanomonas elyunquensis, were both shown to degrade DCM. The
byproduct and isotope analysis of the two bacterium’s ability to degrade 13C-DCM
led to the conclusion that they use separate pathways from one another. The
mixed culture Consortium RM was found to degrade via oxidation of
a

13

C-DCM to

13

C-CO2 molecule while the D. formicoaceticum was found to degrade the

labeled by reducing

13

C-DCM into acetate primarily. D. formicoaceticum was also

found to incorporate the degraded

13

C-DCM into amino acids, meaning it is using

DCM as a primary growth substrate and partially storing the biomass in amino
acids. The discovery can aid future bioremediation scientists set out to identify
the intermediates within the Wood-Ljungdahl pathway contributing to the
degradation of 13C-DCM.
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1.6 Chapter I Appendix
1.6.1 NMR data for the fermentation of DCM in the mixed culture
consortium RM
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34

35

36

37

38

39

40

41

1.6.2 Metabolite integration values observed during fermentation of DCM in
the mixed culture consortium RM
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43

44

45

46

47

48

49

50

51

52

53

54

peak identity

Formate DCM

peak shift ppm

day

DCM

methanol

8.4

5.59

5.29

3.85

3.52

1

0

4.98

4.05

9.61

0

2

0.42

4.41

3.79

13.02

0

4

0.22

3.41

2.72

15.19

0

5

0

3.48

2.72

11.88

0.2

8

2.25

2.35

13.55

0.55

9

2.02

1.98

12.88

0.62

10

1.6

1.44

12.4

0.7

11

1.64

1.33

12.68

0.69

16

0.55

0.5

12.44

0.72

18

0.59

0.44

12.67

0.85

22

0

0

12.75

0.83
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peak identity

acetate

peak shift ppm

day

3.07

2.92

2.17

1.89

1

1.5

23.71

0.37

1.53

2

2.2

23.25

0.56

7.04

4

3.4

20.98

1.2

10.49

5

3.5

20.05

2.25

12.21

8

8.8

19.05

3

17.05

9

11.53

15.75

5

22.31

10

11.96

13.48

4.97

23.47

11

12.05

14.08

5.27

24.67

16

11.75

13.48

6.39

31.97

18

12.2

14.61

6.48

32.49

22

12.25

14.25

6.31

35.3
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peak identity

methane

peak shift ppm

day

1.03

0.90

0.82

0.16

1

0

0

0

0

2

1.43

0.33

0

2.2

4

6.27

4.02

0

5.71

5

8

4

0.2

8.51

8

11

4.75

1.2

12

9

12.21

3.19

2.14

14.33

10

12.64

3.01

2.34

13.87

11

13.2

2.91

2.46

13.73

16

15.75

2.62

3.11

13.9

18

15.98

1.34

3.01

13.95

22

16.59

0.2

2.78

14.03
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1.6.3 NMR data for the fermentation of DCM in the pure culture D. formicoaceticum
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59

60

61

62

63

64

65

66

67

68

69
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1.6.4 UPLC-HRMS isotope analysis of amino acids in the pure culture D.
formicoaceticum

71

72

Ion counts

Asparagine
400000
350000
300000
250000
200000
150000
100000
50000
0
Parent

C-1

C-2

Isotope

73

74

75

76

Ion counts

Proline
1600000
1400000
1200000
1000000
800000
600000
400000
200000
0
Parent

C-1

C-2

Isotope

77

78

79

80

81

medMz

medRt

compound

Extract

90.05556 2.038353 Parent

Alanine/Sarcosine

510708.3

91.05882 2.026313 C-1

Alanine/Sarcosine

403299.9

92.06223 1.439912 C-2

Alanine/Sarcosine

142617.9

104.0711 1.998793 Parent

Dimethylglycine

134654.2

105.0743 1.450243 C-1

Dimethylglycine

31548.46

106.0777 1.262513 C-2

Dimethylglycine

24448.15

106.0502 1.520555 Parent

Serine

114759.6

107.0532 1.387102 C-1

Serine

15620.98

116.0709 2.033003 Parent

Proline

792988

117.0742 2.137901 C-1

Proline

1480297

118.0772 1.666046 C-2

Proline

1425148

118.0865 2.341387 Parent

Valine/betaine

1061125

119.0898 2.182072 C-1

Valine/betaine

1390479

120.0932 1.735646 C-2

Valine/betaine

1568923

121.0965 1.706818 C-3

Valine/betaine

726877.9

122.1

Valine/betaine

201749.1

1.636047 C-4

120.0657 1.820965 Parent

Homoserine/Threonine 278667.3

121.0689 1.616055 C-1

Homoserine/Threonine 354903.4

132.0656 1.560654 Parent

Hydroxyproline

99272.32

133.0688 1.355835 C-1

Hydroxyproline

49368.2

134.0718 1.350368 C-2

Hydroxyproline

44679

132.1019 2.593606 Parent

Leucine/Isoleucine

246546.3

133.1053 2.355987 C-1

Leucine/Isoleucine

449267.1

134.1085 2.333281 C-2

Leucine/Isoleucine

647558.8

135.1124 2.34501

C-3

Leucine/Isoleucine

535746.6

136.1147 2.395774 C-4

Leucine/Isoleucine

277009.7

137.1182 2.231128 C-5

Leucine/Isoleucine

70270.86

133.0606 1.591805 Parent

Asparagine

359195.2
82

134.0635 1.655572 C-1

Asparagine

117703.1

135.0669 1.214862 C-2

Asparagine

61341.86

133.097

Ornithine

1287999

134.0996 1.844426 C-1

Ornithine

222552.4

135.1037 1.72533

C-2

Ornithine

289038.6

136.1075 1.896127 C-3

Ornithine

134018.2

137.1095 1.921341 C-4

Ornithine

36055.22

147.0763 1.95963

Glutamine

161196

148.0797 1.215922 C-1

Glutamine

230518.6

149.0824 1.379565 C-2

Glutamine

174261.9

150.0861 1.488503 C-3

Glutamine

86058.13

147.1127 2.140954 Parent

Lysine

1.65E+07

148.1156 1.604278 C-1

Lysine

3.99E+07

149.1193 2.065016 C-2

Lysine

4.28E+07

150.1228 2.023733 C-3

Lysine

2.33E+07

151.1262 1.951239 C-4

Lysine

6660024

148.0603 1.558416 Parent

O-Acetyl-L-serine

5.68E+07

149.0638 1.395571 C-1

O-Acetyl-L-serine

1.27E+08

150.067

1.557698 C-2

O-Acetyl-L-serine

1.18E+08

151.0704 1.499365 C-3

O-Acetyl-L-serine

5.21E+07

152.0745 1.503946 C-4

O-Acetyl-L-serine

1.03E+07

153.077

O-Acetyl-L-serine

466938.4

150.0582 2.214891 Parent

Methionine

81658.06

151.0613 2.397193 C-1

Methionine

167435.5

152.0649 2.387696 C-2

Methionine

152272.7

153.0683 2.322215 C-3

Methionine

56400.59

153.0769 1.918978 Parent

Xylitol

466938.4

154.0778 1.243878 C-1

Xylitol

64527.67

175.1187 2.228052 Parent

Arginine

2773770

2.257159 Parent

Parent

1.312515 C-5
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176.1221 2.150203 C-1

Arginine

7109984

177.1263 1.916884 C-2

Arginine

7668734

178.1287 2.074697 C-3

Arginine

4005241

179.1314 2.336709 C-4

Arginine

955246.3

180.1366 2.24359

Arginine

80939.45

176.1029 1.345181 Parent

Citrulline

46957.82

177.1062 1.281175 C-1

Citrulline

45953.77

189.1232 1.785991 Parent

Acetyllysine

2595518

190.1265 1.570015 C-1

Acetyllysine

8411805

191.1293 2.184215 C-2

Acetyllysine

1.36E+07

192.1338 2.130339 C-3

Acetyllysine

1.10E+07

193.1371 2.031776 C-4

Acetyllysine

5625792

194.1398 2.122633 C-5

Acetyllysine

1659054

195.1429 2.051494 C-6

Acetyllysine

281593.9

241.0306 1.386174 Parent

Cystine

1579448

242.0352 1.527843 C-1

Cystine

118720.3

245.0778 2.544901 Parent

Uridine

1.84E+08

246.0819 2.513394 C-1

Uridine

2.35E+07

247.0834 2.655957 C-2

Uridine

1199255

248.0871 2.629176 C-3

Uridine

233270.9

C-5
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CHAPTER II
EVALUATION OF SYNTHETIC GLUCOCORTICOIDS CONSISTING
OF STEROIDAL AND NON-STEROIDAL SCAFFOLDS FOR
POTENTIAL AS A DISSOCIATED STEROID
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2.1 Abstract
Glucocorticoids (GCs) have been effective in medicine for the treatment of
certain cancers, autoimmune-mediated disorders and management of immune
response during organ transplantation. The glucocorticoid receptor (GR) (Figure
15) is expressed across all mammalian cells and tissues, making it a valuable
target for drug synthesis. The two major gene transactivation pathways
glucocorticoids play a role in cells are transactivation and transrepression. A
glucocorticoid that can separate the two pathways is heavily sought after. Both
steroidal and non-steroidal glucocorticoids are actively researched and
developed in hopes of finding a molecule with increased anti-inflammatory
properties

(transrepression)

(transactivation).

while

reducing

Previously reported

the

long-term

side

effects

1-(4-fluorophenyl)pyrazole-based

GC

analogues and steroidal C-21 heteroaryl thioethers acting as GR agonists have
been shown to reduce IL-6β induced inflammation (transrepression), but were
accompanied by an unwelcomed upregulation of

pro-inflammatory genes

associated with GC-induced diabetes, muscle wasting, and osteoporosis
(transactivation).55,

56

Discovery of an anti-inflammatory GC with a therapeutic

profile that minimizes transactivation could greatly influence the treatment and
prevention of inflammation induced T1DM. In this study, an unexplored series of
non-steroidal

glucocorticoid

scaffolds

containing

1-(4-substituted

phenyl)

pyrazole-based GC analogues as well as steroidal glucocorticoid scaffolds with a
2-mercaptobenzothiazole modification were synthesized, purified and screened
for structure-activity relationships that lead to the desired therapeutic profile.
Compounds 11aa and 11ab were found to have improved properties, including
anti-inflammatory efficacy comparable to dexamethasone, as well as reduced
ability to suppress pancreatic -cell insulin secretion. Repression of IL-1βinduced inflammation by molecules 11aa and 11ab at 1 µM were comparable to
dexamethasone at 10 nM, while also having similar GRE activation. Compound
11aa reduced insulin secretion at levels compared to the control
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Figure 15: Glucocorticoid receptor 5NFP
Budesonide is show within the binding domain of the glucocorticoid receptor. The binding domain is circled in pink
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DMSO, while dexamethasone reduced insulin secretion 6-fold. Results from the
biological testing of these compounds suggest this molecular scaffold to have
therapeutic value in treating inflammation in patients whom require unabated
insulin function. The steroidal GC scaffold analogues synthesized displayed an
interesting profile

while

mercaptobenzothiazole

subjected

modification

to

the

greatly

two

derivatizations.

improved

the

The

2-

transactivating

properties of the steroids although negatively impacted the transrepressive
properties. The second derivatization with 2-furoyl had the opposite effect
whereas the addition to the steroid backbone greatly improved the ability to
repress the expression of cytokines. Compounds 3c and 3d, displayed the most
promising transrepressive profile while compounds 2b and 2c displayed the most
favorable transactivating profile.

2.2 Introduction
2.2.1 Discovery of glucocorticoids
In the 1930’s at Princeton University, Wilbur W. Swingle (1891-1975) and Joseph
J. Pfiffner (1903-1975) had undertaken the task of extracting “the hormone”
thought to be responsible for the symptoms of Addison’s disease. The extracted
material was found to be a crude mixture of several compounds and it was not
until Edward C. Kendall (1886-1972) at the Mayo clinic was able to separate the
final product from epinephrine and believed it to be “the adrenal cortical
hormone”. The hormone Kendall was able to

purify was later renamed as

cortisone, and is now known today as the first discovered glucocorticoid (GC) or
corticosteroid produced from the adrenal gland.57 Kendall later received the 1950
Novel Prize for Physiology or Medicine for the discovery of the molecule.
Interestingly enough, it was not found out until years after the discovery and the
Nobel Prize given out that the team of Swingle and Pfiffner at Princeton in fact
did isolate cortisone all along although they failed to recognize it’s biological
significance.58 The first medicinal application of cortisone came soon after its
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discovery as it was administered at the Mayo clinic in 1945 for the treatment of
Rheumatoid Arthritis. Multiple more glucocorticoids were discovered over the
next decade as it was observed that small manipulations to eight positions on the
steroid skeleton of cortisone caused varying anti-inflammatory effects. (Figure
16)
It was discovered that small alterations to the skeleton of cortisone produced a
different anti-inflammatory profile with C6, C10, and C16 bringing about the
largest change. The first analogues of cortisone and hydrocortisone to be
synthesized and clinically used were metacortandracin and metacortandrolone in
1954.59 The compounds were later renamed prednisone and prednisolone,
respectfully. The synthetic glucocorticoids exhibited anti-inflammatory effects 4-5
times greater than their natural counterparts.60 The synthetic glucocorticoids
discovered following include fludrocortisone in 1954, triamcinolone in 1956,
methyl-prednisolone in 1957 and dexamethasone in 1958, all still in use today. 6164

The term or name glucocorticoid originated from its role in the metabolism of

glucose, synthesis in the adrenal cortex and the steroidal structure.
Glucocorticoids are steroid hormones, possessing both anti-inflammatory and
metabolic effects, synthesized endogenously in the adrenal glands. GCs operate
by acting as a ligand for the glucocorticoid receptor (GR), located in the cellular
cytoplasm bound to chaperone proteins. The GR is expressed by nearly all cell
types, including pancreatic β-cells, and is the product of a single gene, NR3C1,
that is post-translationally modified to produce functionally distinct subtypes of
the GR.65 It was discovered that small alterations to the skeleton of cortisone
produced a different anti-inflammatory profile with C10, C6, and C16 bringing
about the largest change.
The first analogues of cortisone and hydrocortisone to be synthesized and
clinically used were metacortandracin and metacortandrolone in 1954. 59 The
compounds were later renamed prednisone and prednisolone, respectfully. The
synthetic glucocorticoids exhibited anti-inflammatory effects 4-5 times greater
than their natural counterparts.60 The synthetic glucocorticoids discovered
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Figure 16: Cortisone steroid skeleton.

following include fludrocortisone in 1954, triamcinolone in 1956, methylprednisolone in 1957 and dexamethasone in 1958, all still in use today. 61-64
The term or name glucocorticoid originated from its role in the metabolism of
glucose, synthesis in the adrenal cortex and the steroidal structure.
Glucocorticoids are steroid hormones, possessing both anti-inflammatory and
metabolic effects, synthesized endogenously in the adrenal glands. GCs operate
by acting as a ligand for the glucocorticoid receptor (GR), located in the cellular
cytoplasm bound to chaperone proteins. The GR is expressed by nearly all cell
types, including pancreatic β-cells, and is the product of a single gene, NR3C1,
that is post-translationally modified to produce functionally distinct subtypes of
the GR.65
2.2.2 Glucocorticoid bioactivity
The GR has at least six modes of activation at the cellular level. The ligandbound GR (GR-GC) can translocate to the nucleus, whereby it can bind to a
glucocorticoid-response element (GRE) to (1) induce or (2) suppress gene
expression; additionally, while in the nucleus the GR-GC can (3) facilitate or (4)
hinder the actions of other transcription factors. Alternatively, the GR-GC can
remain in the cytoplasm and (5) increase, or (6) decrease, the activity of proteins
in the cytoplasm.66 Due to the anti-inflammatory and metabolic-altering effects of
GCs, along with the ubiquity of the GR, GC-based therapies have been
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successfully applied to treating a wide range of inflammatory, auto-immune
disorders, and cancers as well aiding in organ and tissue transplantation. 66, 67
Application of synthetic GCs as a possible anti-inflammatory drug for type 1
diabetes mellitus (T1DM) and immunosuppressive agent for organ transplants is
attractive for a variety of reasons. Diabetes is the seventh leading cause of death
in the United States, affecting 29.1 million people or 9.3% of the U.S. population
in 2014.68, 69 Diabetes also serves as a major cause of heart disease and stroke
and is the leading cause of kidney failure, non-traumatic lower limb amputations,
and new cases of blindness in adults.68
T1DM is an autoimmune disorder characterized by inflammation and subsequent
autoimmune-mediated destruction of the insulin-producing β-cells.70 One manner
of autoimmune β-cell death commonly associated with T1DM occurs through
insulitis, a process by which β-cell damage and death occur via infiltration by
macrophages and T-cells due to an accumulation of pro-inflammatory cytokines
such as IL-1β, IFN-γ, and TNF-α.71-73 Cytokine-mediated inflammation of β-cells
causes the expression of chemokines CXCL9 and CXCL10, which through
binding to integral membrane protein CXCR3 signals the recruitment of T-cells
followed by infiltration and cell death.71, 74, 75
The ideal GC-based T1DM therapeutic would suppress the autoimmune
response, which ultimately destroys the β-cells. Moreover, synthetic GCs are
designed to exhibit a "dissociated profile,” that is - possessing enhanced antiinflammatory activity with reduced side effects. Despite incredible beneficial
properties of GCs, they pose a long list of serious side effects including
Cushing's disease, metabolic syndrome, osteoporosis, and diabetes. In fact, the
most common cause of drug-induced diabetes is clinical administration of GCs,
and the incidence of GC-induced diabetes continues to rise.76
Two of the six modes of activation for the GR are often focused on as being the
major contributors of the deleterious and salutary effects. One being the
translocation of the GR-GC to the nucleus to increase transcription of proinflammatory genes, termed transactivation. The metabolic deregulation caused
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by the direct binding of the GR-GC to GREs is thought to cause several side
effects including those already mentioned, as well as hypertension and
hyperglycemia. The other significant mode of GR activation results in
translocation of the GR-GC to the nucleus to inhibit the action of proinflammatory cytokines, such as IL-1β, NF-κB, or AP-1, termed transrepression.
2.2.3 Steroidal vs. non-steroidal glucocorticoid scaffolds
Glucocorticoids can further be broken down by compounds classes and
ultimately the targeting receptor. Molecules that selectively target the
glucocorticoid receptor are commonly known as selective glucocorticoid receptor
agonists (SEGRAs). Historically the first SEGRA molecules were synthetic
steroids with a scaffold containing the bound four ring structure. (Figure 17)
It was not until the 1960’s that molecules targeting the GR that did not contain
the typical 4-ring steroid scaffold were synthesized.
The new non-steroidal glucocorticoid scaffolds offered researchers more
information into the structure-activity relationship between the GR and GC due to
the limited or already exhausted all manipulations previously done on the 4-ring
steroid scaffold.
The steroidal GC scaffold’s described herein were inspired by previous work
done on the derivatization of hydrocortisone using a mercaptobenzothiazole and

Figure 17: Steroid scaffold
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furoyl modification.56 The hydrocortisone analogues synthesized displayed
moderate inhibitory activity towards transrepression factor IL-6 and a feeble
induction of tyrosine amino transferase in both rat and human cells. 77 The nonsteroidal GC scaffolds described in this work were inspired by a set of molecules
synthesized with interesting bioactivity. Shah and Scanlan in 2004 developed a
series of novel arylpyrazole compounds that are ligands of the GC receptor
(Figure 18).78 The binding affinity of the set of 15 molecules originally
synthesized by Shah and Scanlan were comparable to

prednisolone,

dexamethasone and cortisol. The repression of various pro-inflammatory genes
through the direct binding of the GR-non-steroidal GC to transcription factors are
thought to be responsible for the observed anti-inflammatory effects of GCs
scaffolds discovery within the last 20 years.79-92
Different GREs differentially affect GR-GC binding conformation which implies
that a GR-GC that cannot bind one GRE may be able to bind another GRE
transcriptional cofactors are dependent on the cell or tissue type, and interactions
with the GR-GC and other transcription factors contribute to the activity and

Figure 18: Merck scaffold is a hybrid structure of dexamethasone and
flurocortivazol
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based on the specific target gene. Furthermore, different types and ratios of
dissociative properties of the GR-GC in terms of tissue type.67, 93-97 Synthetic GCs
have been shown to improve β-cell development and suppress inflammation
induced by IL-1β;98, 99 However, they have also been shown to reduce adult β-cell
mass.100, 101 In this study, a series of novel non-steroidal scaffold, 1-(4-substituted
phenyl)pyrazole-based GC analogues and a series of steroidal scaffold 2mercaptobenzothiazole GC analogues have been synthesized and subjected to
in vitro assays measuring transactivation and transrepression. The top
candidates from these assays were further assayed to determine how insulin
production was affected.
2.2.4 Biological activity of 2-mercaptobenzothiazole
Over the past two decades medicinal chemistry began to see a large increase in
therapeutic agents containing a heterocycle. This is due to the proven utility of
the compound class. 2-Mercaptobenzothiazole (MBT) (Figure 19) a bicyclic
compound containing two hetero atoms has shown to be associated with multiple
biological activities making it a prime compound class for derivatization of
potential drug targets. Derivatives of MBT have shown to have varying biological
activities, S-acyl and S-acethydrazide hydrazine possessed antifungal and
antibacterial activities, 2-(thiocyanomethylthio)benzothiazole possessed strong
antifungal activity and 2,2’-dithiobisbenzothiazole has been used as an
insecticide as well as a fungicide.102-106

Figure 19: 2-Mercaptobenzothiazole
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The anti-inflammatory activity of MBT has been reported in past literature and
has shown selectivity specific enzymes. In an effort to target the cyclooxygenase2 (COX-2) enzyme a class of pentadecylbenzyl compounds were derivatized with
MTB and increase selectivity 470-fold targeting COX-2 over COX-1.107 MTB’s
anti-inflammatory activity was compared to aliphatic/alicyclic rings as derivatives
in the study of carrageenan-induced hind paw edema in rats. MTB proved to
have better anti-inflammatory than all heterocycle counterparts.108 MTB was
previously used targeting the GR as a derivatization agent with excellent
dissociation profile maintaining efficacy against pulmonary inflammation that also
lessened side effects of transactivation.98, 109-111

2.3 Synthesis and Purification
2.3.1 Synthesis of non-steroidal glucocorticoids
The total synthesis of all 1-(4-substituted phenyl)pyrazole-based GC analogues
tested in this study were prepared by a previously described synthesis for a
series of GC analogues55 with a few modifications made to the published method
(Figure 20). A simple change of reagent is employed in the conversion of
secondary alcohol 11 to ketone 12, accomplished using a standard PCC
(pyridinium chlorochromate) oxidation in place of the costly oxidation with TPAP
(tetrapropylammonium perruthenate) using N-methylmorpholine-N-oxide (NMO)
as a sacrificial oxidant. The molecules investigated by Ali et al. (Merck 2004)
focused on alterations to the R2 moiety while leaving the 4-fluorophenyl R1 group
as a constant. Changing the identity of R1 was realized through the addition of
the appropriate phenylhydrazine to β-ketoaldehyde 6, thereby installing the
desired R1-arylpyrazole moiety (termed “headgroup”). Additionally, to further
enhance the scope of functionalities examined in our biological evaluation was
included a cyanomethylene unit as an R2 moiety (termed “sidegroup”) previously
unexamined in this type of structure-activity experiment. Ideally for reactions that
create enantiomers or diastereomers, chiral HPLC would be employed.
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Figure 20: Synthetic route for the synthesis of non-steroidal glucocorticoid
compounds
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Chiral HPLC was not employed in the purification of the GC analogues, but
rather solely standard bench-top flash chromatography (specific procedure can
be found in chromatographic methods) and trituration techniques were employed.
Because of such purification methodology, extra steps towards the production of
aldehyde 10 and 2° alcohols 11 were taken to prevent co-mingling of molecules
bearing identical Rf values by TLC analysis.
Briefly, the total synthesis of the steroid core begins with a Robinson annulation
of compounds 1 and 2 to form intermediate trione 3, which upon asymmetric
intramolecular cyclization gives Wieland-Miescher ketone 4. Selective ethylene
glycol protection of compound 4 leaves the α-β-unsaturated ketone available for
enolate formation and subsequent addition to ethyl formate, giving βketoaldehyde 6. Addition of the appropriate phenylhydrazine to 6 completes the
core structure of the 1-(4-substituted phenyl)pyrazole-based GCs as compounds
7. The acid-catalyzed deprotection of acetal 7 provided synthon 8, which was
formylated via Wittig reaction to afford aldehyde 10, the essential intermediate for
the divergent synthesis of all analogues presented in this study. Separation of
starting material from the product of the one-pot Wittig/hydrolysis sequence from
ketone 8 to aldehyde 10 was futile. To obtain aldehyde 10 in high purity, the
intermediate enol-ether 9 was isolated from the Wittig reaction, purified via flash
chromatography to remove any unreacted starting material, and subsequently
subjected to hydrolysis conditions to afford compound 10 in sufficient purity to
proceed with the next reaction.
Insertion of the sidegroup (R2) into the GC scaffold was achieved through
generation of the appropriate alkyl lithium reagent followed by addition of
aldehyde 10, resulting in a series of 2˚ alcohols (11) that were subjected to
biological testing. Intermediate ketone 12 was obtained through a PCC oxidation
of 11, and after purification was treated with MeLi to afford a series of 3˚ alcohols
(13), which were also assayed. Synthesis of undesired byproducts 11ag and
13ag were attempted using the reaction conditions for generating compounds 11,
12, and 13. Persistent 1H-NMR impurities of purified target compounds 11ad,
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11ae, and 11af prompted the need to synthesize a t-butyl analogue of compound
11. Addition of t-BuLi to aldehyde 10a was achieved using reaction conditions
described in generating the GC analogues in question - with consideration to the
overall polarity of the reaction solvent system. The reaction to make 11ag would
not proceed if the volume of polar organic solvent was ≤ 50% of the total solvent
volume. Even though t-BuLi is generally a poor nucleophile for additions to
carbonyl compounds, the reaction of t-BuLi with aldehyde 10 produced a pure
yield ~25% suggesting a non-negligible amount of 11ag is being produced in the
reactions affording 11ad, 11ae, and 11af. Compound 13ag could not be
synthesized under the reaction conditions used for generating the other
compound 13 analogues, ketone 12ag was recovered from a reaction with 10
equivalents of MeLi with minimal evidence of 13ag being synthesized – this was
verified by performing an HPLC analysis of crude recovered material where 12ag
was detected as the major component, and 13ag was detected as less than
0.1% of the signal intensity of 12ag.
2.3.2 Purification of non-steroidal glucocorticoids
Throughout the synthetic procedure there are purification steps that require
silica-based flash chromatography. Thin-layer chromatography (TLC) analysis
typically done using a 25% solution of ethyl acetate (EtOAc) in hexanes,
visualization of resolved compounds using short-wave ultra-violet (UV) light
reveals separations that do not seem challenging, but when applied to a flash
column by routine methods result in poor separation. The best chromatographic
resolution was obtained using a silica stationary phase and a low-polarity mixture
of EtOAc in hexanes as the mobile phase. Other mobile phases such as
petroleum

ether/

diethyl

ether

(PetEt/Et2O),

Et2O/pentane,

methanol/

dichloromethane (MeOH/DCM), or tetrahydrofuran (THF)/hexanes proved to be
less effective toward the isolation of the target compounds. Dissolution of the
compounds in halogenated solvents allows for wet-loading concentrated
solutions to the top of the column but will create unwanted band-broadening. All
99

the compounds purified in this synthesis would dissolve mostly in polar solvents
that would obscure the chromatography and result in poor separation. It was
found that the best chromatographic resolution can be obtained by loading
compounds onto silica, wet-packing the silica column, carefully placing a thin
layer of sand to maintain column integrity during compound loading, and finally
loading the vacuum-dried compound-adsorbed silica on top of the sand layer.
This procedure mimics that of a typical TLC analysis where the compound is
loaded onto a small section of silica, the solvent evaporates, and then mobile
phase added.
The compounds subjected to biological testing in this preliminary study have an
objective purity ~80% by 1H-NMR analysis, which is due to subtle differential
intramolecular relaxation effects, as well as the presence of diastereomers of the
final compounds. For compounds bearing R2 = 2,3-diflouoroanisolyl, 3-thiophenyl,
and cyanomethyl - a single byproduct could not be removed by the
chromatographic methods employed throughout the synthesis of the target
compounds. The byproduct in question originates from the conversion of 10 to
11, where freshly generated organolithium species using t-BuLi are added to
aldehydes 10. Being that lithium-halogen exchange reactions are an equilibrium
process based on the comparative stability between the exchanging species,
these reactions will always generate an amount of the undesired “t-butyl adduct”,
which was synthesized and subjected to the same bioassays as all other
compounds to determine how the presence of this undesired byproduct affected
the observed activities of the screened GC analogues. All intermediates were
only carried forward if TLC analysis revealed the purified compound as a single
spot by UV visualization and/or TLC staining. Although the synthetic GCs
subjected to ex-vivo biological testing were not pure single molecules, the fact
that these “impurities” were found in nearly all the compounds assayed should
indicate that the observed activities for the compounds tested are directly related
to the desired synthetic GC analogue.
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2.3.3 Stereochemistry of non-steroidal glucocorticoids
The synthetic scheme for the non-steroidal glucocorticoids in figure 20 includes
enantiomeric and diastereomeric excess (ee, de) percentages listed for
analogues 4 through 13. Chiral centers were introduced into the structure at the
synthesis of analogues 4, 10, 11 and 13. The enantiomers/diastereomers where
not separated due to the study being an initial screening for bioactivity. The
insertion of the first chiral carbon at molecule 4 was an asymmetric
intramolecular cyclization using the L-proline protocol to synthesize the WielandMiescher ketone.112 The selectivity reported for the conversion to the WielandMiescher ketone was 70% ee. The enantiomers were carried through the
reaction steps until the addition of the second chiral carbon using a Wittig
reaction to form molecule 10. The installment of the aldehyde was done similar to
the reported synthetic step in the 2004 synthesis of the Merck scaffold.55 They
reported a diastereomeric ratio of 8:1, which combined with the previous
enantiomeric excess of 70% ee would produce a 2% ee and 52% de for molecule
10. The final two carbon centers in the synthesis were installed in secondary
alcohol 11 and the tertiary alcohol 13. Ali and coworkers reported only a single
diastereomer was afforded in both steps. Therefore, the enantiomeric/
diastereomeric excess ratios of 2% and 50% were carried through molecule 13.
2.3.4 Synthesis of steroidal glucocorticoids
The total synthesis for the steroidal glucocorticoid scaffold analogues tested were
prepared

with

a

previously

published

synthesis

on

modifications

to

hydrocortisone with slight modifications.111 A total of 10 molecules were
synthesized using 6 different synthetic glucocorticoids. A general procedure for
the construction of the steroidal GC scaffold analogues is presented in figure 21.
The commercially available synthetic glucocorticoid 1a-f was converted to the
intermediate mesylate with the use of N,N-Diisopropylethylamine (DIPEA) in
dichloromethane. The mesylated steroid was not purified and the crude product
was reacted directly with 2-mercaptobenzothiazole to afford products 2a-f. For
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the second derivatization of the synthetic steroids, 2a-d were subjected to a
reaction with furoyl chloride under basic conditions to afford products 3a-d
2.3.5 Purification of steroidal glucocorticoids
The objective was to obtain a purity of >99% for this set of molecules moving
forward to biological testing. The commercially available purchased synthetic
glucocorticoids arrived with purity ranging from 95%-99%. All purification was
done on normal phase column chromatography using silica gel as the stationary
phase with various mobile phases being used. All crude products were dry
loaded onto columns adhered to silica to limit the amount of line-broadening as
the mobile phase was added. The initial conversion 1a to 2a was done in two
steps with purification of the mesylate intermediate before conversion to the
mercaptobenzothiazole derivative. The overall yield of the two steps was 80% in
the first series of derivatives synthesized for the dexamethasone analogue, 2a.
The yield forgoing the purification of the mesylate intermediate and subsequent
reaction with the 2-mercaptobenzothiazole yielded 70% conversion. It was
determined that the rest of the derivatives would forgo the initial purification of the
intermediate and save time and money. The purification of the mesylate required
large amounts of silica and solvent and upon purification the compound would
need to be dried under vacuum before it can be used in the reaction with 2mercaptobenzothiazole. The purification of 2a-f was aided through TLC of the
reaction while it was being actively stirred. The starting material will be
completely consumed given the correct amount of time and molar equivalency
added through both the methylation and mercaptobenzothiazole derivatization.
The reactions were monitored and only stopped when the starting material was
not visible on a TLC plate using a potassium permanganate (KMnO 4) stain. The
KMnO4 stain proved to be more sensitive towards this particular set of molecules
over simply observing the compound under the UV light. 2a-f were purified using
a silica gel stationary phase with a mobile phase made up of 25%
EtOAc/hexanes.
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Figure 21: Synthetic route for the synthesis of the steroidal glucocorticoid scaffold analogues
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Each product was found to be a white solid upon drying off column solvent.
Products 3a-d proved a challenging purification. The separation was difficult due
to the byproducts and remaining starting material having very similar retention
factors. The previous literature mentioned the reaction should be halted upon
complete consumption of the starting material. Although in the synthesis of 3a-d,
starting material was found in each of their respective crude oils after reaction
completion. Several trouble shooting steps were undertaken, and reactions were
done increasing the heat as well as time stirring. Neither option proved
worthwhile as trace amounts of starting material remained after analysis by 1HNMR. In fact, adding heat caused the addition of a second furoyl group to the
molecule. The purification following literature on similar molecules was done
using a silica stationary phase with a mobile phase consisting of 1%
methanol/chloroform solution. This was sufficient column for most of the
byproducts in the crude oil except for the starting material. To separate 3a-d from
2a-d a non-protic polar solvent was needed. For this, a gradient mobile phase
was used starting at a concentration of 5% EtOAc/hexanes and eluting at 25%
EtOAc/hexanes. Each of the compounds had a purity >97% upon analysis by 1HNMR

2.4 Molecular Modeling
To better understand the results from the data obtained from bioassays, ligandreceptor interactions were modeled between the synthesized non-steroidal GC
molecules subjected to ex-vivo testing and the human glucocorticoid receptor
(PDB ID: 5NFP)113. Ligand models were prepared in Chem3D (PerkinElmer) to
generate a structure in the lowest-energy conformation to be used in the docking
experiment. Docking was performed between the rigid 5NFP GR and the flexible
ligands generated from Chem3D using AutoDock Vina (The Scripps Research
Institute)114, and the resulting docking conformations were viewed in 3D with
PyMol (Schrödinger).115 2D ligand-residue interaction figures were generated
with LigPlot+ (European Molecular Biology Laboratory)116. 2D and 3D
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representations of the modeled interactions as well as calculated binding
affinities (AutoDock Vina) can be found in the supporting information document
(section 7). Ligand-residue interactions obtained from analysis using LigPlot+
were tabulated and further processed in R to create an interaction map. (Figure
22)

2.5 Materials and Methods
2.5.1 Non-steroidal glucocorticoid synthetic procedure
Procedures for obtaining compound 6 were followed from a previously reported
synthesis of N-arylpyrazolo[3,2-c]-based GC derivatives. The same general
procedure can be followed for obtaining both tolyl- and anisolyl- (R1 = 1(4methylphenyl);

1-(4-methoxyphenyl))

GC

analogue

series

starting

from

compound 6, the point of synthetic originality for this study. Synthetic procedures,
chromatographic methods, and characterization data for intermediates and
previously reported GC analogues will not be shown (namely the fluorophenyl
series of GC analogues) except for GC analogues which were subjected to
biological testing.
General procedure for GC headgroup installation - compound series 7: To a
solution of 6 (5.0 g, 20 mmol) in glacial acetic acid (50 mL) was added the
appropriate phenylhydrazine HCl salt (23 mmol) and sodium acetate (1.88 g, 23
mmol) and allowed to stir at room temperature for 2 h. The reaction mixture was
then slowly and carefully poured into a cold (0-5 ˚C) and actively stirred solution
of saturated NaHCO3. The neutralized solution was then extracted with EtOAc
(5x100 mL), washed with brine, dried with anhydrous MgSO 4, filtered, and
concentrated in vacuo. Purification of the crude product was accomplished using
flash chromatography (20% EtOAc/hexanes) to give a viscous orange oil.
4a-methyl-1-(p-tolyl)-1,4,4a,6,7,8-hexahydrospiro-[benzo[f]indazole-5,2'[1,3]dioxolane] (7b): From 6 using p-tolylphenylhydrazine HCl. Yield = 44%.
TLC Rf = 0.28 (30% EtOAc/hexanes). 1H-NMR (CDCl3, 500 MHz) δ 1.21 (s, 3H),
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Figure 22: Ligand-residue interaction map
(left) displaying hydrophillic (pink) and hydrophobic (blue) interactions from Autodock Vina™ molecular docking
simulations. The top binding conformation of compound 11aa is shown in the 5nfp binding pocket (right). Ligand
shown with a green carbon skeleton while the residues are shown with a grey carbon skeleton. Heteroatoms are
displayed in a typical fashion – N (blue); O (red); S (yellow); Hydrogen bond (cyan
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1.65-1.83 (m, 4H), 2.28 (dt, 2H), 2.4 (s, 3H), 2.51 (d, 1H), 3.16 (d, 1H), 3.99-4.08
(m, 4H), 6.23 (s, 1H), 7.24-7.26 (d, 2H), 7.35-7.37 (d, 2H), 7.43 (s, 1H).
1-(4-methoxyphenyl)-4a-methyl-1,4,4a,6,7,8hexahydrospiro[benzo[f]indazole-5,2'-[1,3]dioxolane] (7c): From 6 using pmethoxyphenylhydrazine

HCl.

Yield

=

38%.

TLC

Rf

=

0.27

(50%

EtOAc/hexanes). 1H-NMR (CDCl3, 500 MHz) δ 1.22 (s, 3H), 1.68-1.83 (m, 3H),
2.30-2.31 (d, 1H), 2.51-2.54 (d, 2H), 3.15-3.18 (d, 2H), 3.85 (s, 3H), 4.01-4.13
(m, 4H), 6.17 (s, 1H), 6.97-7.41 (m, 5H).
Acetal deprotection for preparation of ketone 8: To a solution of 7 (5.9 mmol)
in THF (50 mL) was added 6 M HCl (3.9 mL, 23.6 mmol) and subjected to reflux
for 3.5 h. The reaction mixture was then neutralized by the slow addition of
saturated NaHCO3 and extracted with ethyl acetate (4x100 mL). The pooled
organic layer was washed with brine, dried with anhydrous MgSO 4, and
concentrated in vacuo. Purification of the crude product was accomplished using
flash chromatography to give a dull orange solid.
4a-methyl-1-(p-tolyl)-1,4,4a,6,7,8-hexahydro-5H-benzo[f]indazol-5-one

(8b):

From 7b. Flash column mobile phase - 15% EtOAc/hexanes. Yield = 72%. TLC
Rf = 0.34 (30% EtOAc/hexanes). 1H-NMR (CDCl3, 500 MHz) δ 1.25 (s, 3H), 1.621.71 (m, 1H), 2.06-2.11 (m, 1H), 2.40 (s, 3H), 2.51-2.57 (m, 2H), 2.60-2.67 (m,
2H), 2.90 (s, 2H), 6.33 (s, 1H), 7.26-7.28 (d, 2H), 7.35-7.38 (d, 2H), 7.48 (s, 1H).
1-(4-methoxyphenyl)-4a-methyl-1,4,4a,6,7,8-hexahydro-5H-benzo[f]indazol5-one (8c): From 7c. Flash column mobile phase - 20% EtOAc/hexanes. Yield =
77%. TLC Rf = 0.28 (40% EtOAc/hexanes). 1H-NMR (CDCl3, 500 MHz) δ 1.24 (s,
3H), 1.60-1.73 (m, 1H), 2.04-2.11 (m, 1H), 2.49-2.69 (m, 4H), 2.93 (d, 2H), 3.85
(s, 3H), 6.26 (s, 1H), 6.95-7.47 (m, 5H).
General Procedure for the synthesis of aldehydes 10: A commercially
available solution of potassium bis(trimethylsilyl)amide in toluene (0.5 M, 33.12
mL, 16.5 mmol) was added dropwise with a syringe to an actively stirred
suspension of methoxymethyltriphenylphosphonium chloride (6.81 g, 19.8 mmol)
in THF (65 mL) cooled to -40 °C. The solution was warmed to 0 °C and stirred at
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that temperature for 15 min and a color change from pale yellow to dark red was
observed. A solution of the appropriate ketone precursor 8 (6.6 mmol) in THF (16
mL) was transferred dropwise via canula to the chilled ylide. After stirring for 24
h, the reaction was quenched by the addition of 1:1 THF/MeOH (16 mL), diluted
with three reaction volumes of EtOAc, washed with water and brine, dried over
MgSO4, filtered, concentrated in vacuo and subjected to flash chromatography
(15% EtOAc/hexanes). Fractions containing enol either 9 were collected,
concentrated in a round bottom flask, and dissolved in THF. To the prepared
solution of 9 in THF was added 4 M HCl and could stir at room temperature for
36 h. The reaction mixture was afterward diluted with EtOAc - washed with water,
saturated NaHCO3, and brine. The organic layer was dried over MgSO4, filtered,
and concentrated in vacuo to give crude aldehyde 10 as a beige solid.
Purification of the crude product was accomplished using flash chromatography
(15% EtOAc/hexanes).
4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazole-5carbaldehyde (10b): Yield = 40.0 %. TLC Rf = 0.31 (25% EtOAc/hexanes). 1HNMR (CDCl3, 300 MHz) δ 1.12 (s, 3H), 1.30-1.40 (m, 2H) 1.70-1.78 (m, 2H),
1.90-1.96 (m, 1H), 2.32-2.44 (m, 2H), 2.40 (s, 3H), 2.91 (d, 1H), 3.10 (d, 1H),
6.21 (s, 1H), 7.26-7.28 (d, 2H), 7.35-7.37 (d, 2H), 7.44 (s, 1H), 9.90 (s, 1H)
1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazole5-carbaldehyde (10c): Yield = 45.0 %. TLC Rf = 0.28 (25% EtOAc/hexanes). 1HNMR (CDCl3, 500 MHz) δ 1.11 (s, 3H), 1.39-1.43 (m, 1H), 1.72-1.75 (m, 1H),
1.90-1.96 (m, 2H), 2.33-2.44 (m, 3H), 2.89-2.92 (d, 1H), 3.08-3.11 (d, 1H), 3.853.86 (s, 3H), 6.15 (s, 1H), 6.95-7.42 (m, 5H), 9.90 (s, 1H).
General Procedure for R2 = methyl 2˚OH analogues: A commercially available
solution of 1.6 M MeLi in Et2O (312 µL, 0.5 mmol) was transferred via syringe to
a round bottom flask containing diethyl ether (5 mL) and cooled to -78 °C. A
solution of the appropriate aldehyde 10 (0.05 mmol) in THF (5 mL) was added
dropwise via canula, and the reaction was stirred at -78 °C for 45 min. The
reaction was quenched with isopropyl alcohol (IPA), poured into a separatory
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funnel containing saturated NH4Cl, and extracted three times with EtOAc. The
organic phase was washed with once each with water and brine, dried over
anhydrous MgSO4, filtered, and concentrated in vacuo. Purification of the crude
product was accomplished using flash chromatography (15% EtOAc/hexanes) to
give a white solid.
1-(4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5yl)ethan-1-ol (11ba): From 10b using MeLi (1.6 M solution in Et2O). Yield = 50%.
Flash column mobile phase – 30-40% EtOAc/hexanes. TLC Rf = 0.16 (30%
EtOAc/hexanes). HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C21H27N2O,
323.21179; found 323.21001. 1H-NMR (CDCl3, 500 MHz): δ 1.13 (s, 3H), 1.231.29 (m, 3H), 1.34-1.45 (m, 2H), 1.56-1.62 (m, 2H), 1.72-1.78 (m, 1H), 1.90-1.94
(m, 1H), 2.27-2.30 (m, 1H), 2.32-2.37 (m, 4H) 2.47-2.50 (d, 1H), 2.97-3.00 (d,
1H), 6.14 (s, 1H), 7.23-7.26 (d, 2H), 7.34-7.36 (d, 2H), 7.40 (s, 1H)
1-(1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1Hbenzo[f]indazol-5-yl)ethan-1-ol (11ca): From 10c using MeLi (1.6 M solution in
Et2O). Yield = 58%. Flash column mobile phase – 30% EtOAc/hexanes. TLC Rf =
0.11 (25% EtOAc/hexanes). HRMS (DART-RTOF) m/z: [M+H]+ Calcd for
C21H27N2O2, 339.20670; found 339.20344. 1H-NMR (CDCl3, 500 MHz): δ 1.13 (s,
3H), 1.23-1.29 (m, 4H), 1.34-1.45 (m, 3H), 1.74-1.78 (d, 1H),1.88-1.95 (d, 1H),
2.28-2.31 (d, 1H), 2.35-2.39 (m, 1H), 2.47-2.51 (d, 1H), 2.98-3.01 (d, 1H), 3.843.87 (s, 3H), 6.10 (s, 1H), 6.96-7.40 (m, 5H).
General Procedure for R2 = phenyl 2˚OH analogues:
A commercially available solution of 1.9 M PhLi in di-n-butyl ether (3.42 mL, 6.5
mmol) was transferred to a round bottom flask containing a small portion of dry
Et2O and was cooled to -78 °C. A solution of 10 (0.65 mmol) in THF (2 mL) was
added dropwise via canula, and the reaction was stirred at -78 °C for 45 min. The
reaction was quenched with IPA, poured into a separatory funnel containing
saturated NH4Cl, and extracted three times with EtOAc. The organic phase was
washed with once each with water and brine, dried over anhydrous MgSO 4,
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filtered, and concentrated in vacuo. Purification of the crude product was
accomplished using flash chromatography.
(4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5yl)(phenyl)methanol (11bb): From 10b using PhLi (1.9 M solution in di-n-butyl
ether). Flash column mobile phase – 15% EtOAc/hexanes, to give a white solid.
Yield = 28%. TLC Rf = 0.20 (30% EtOAc/hexanes). HRMS (DART-RTOF) m/z:
[M+H]+ Calcd for C26H29N2O, 385.22744; found 385.22612. 1H-NMR (CDCl3, 500
MHz): δ 1.26 (s, 3H), 1.60-1.81 (m, 5H), 2.23-2.28 (d, 1H), 2.36-2.43 (m, 4H),
2.74-2.77 (d, 1H) 3.15-3.18 (d, 1H), 5.17 (s, 1H), 6.15 (s, 1H), 7.23-7.27 (d, 3H),
7.34-7.38 (m, 6H), 7.41 (s, 1H).
(1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol5-yl)(phenyl)methanol (11cb): From 10c using PhLi (1.9 M solution in di-n-butyl
ether). Flash column mobile phase – 20% EtOAc/hexanes, to give a beige solid.
Yield = 73 %. TLC Rf = 0.11 (30% EtOAc/hexanes). HRMS (DART-RTOF) m/z:
[M+H]+ Calcd for C26H29N2O2, 401.22235; found 401.21952. 1H-NMR (CDCl3,
500 MHz): δ 1.27 (s, 3H), 1.56-1.81 (m, 6H), 2.24-2.27 (d, 1H), 2.36-2.44 (m,
1H), 2.75-2.78 (d, 1H), 3.17-3.20 (d, 1H), 3.85 (s, 3H), 5.20 (s, 1H), 6.11 (s, 1H),
6.96-7.44 (m, 9H).
General Procedure for R2 = 4-fluorophenyl 2˚OH analogues: A commercially
available solution of 2.0 M 4-fluorophenylmagnesium bromide in diethyl ether
was transferred to a round bottom flask and cooled to -78 °C. A solution of 8 R1
= Me in THF was added dropwise via canula, and the reaction was stirred at -78
°C for 45 min. The reaction was quenched with IPA, poured into a separatory
funnel containing saturated NH4Cl, and extracted three times with EtOAc. The
organic phase was washed with once each with water and brine, dried over
anhydrous MgSO4, filtered, and concentrated in vacuo. Purification of the crude
product was accomplished using flash chromatography to give a white solid.
(4-fluorophenyl)(4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1Hbenzo[f]indazol-5-yl)methanol

(11bc):

From

10b

using

4-

fluorophenylmagnesium bromide (2.0 M in Et2O). Flash column mobile phase –
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10% EtOAc/hexanes. Yield = 11.5 %. TLC Rf = 0.24 (25% EtOAc/hexanes).
HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C26H28FN2O, 403.21802; found
403.21649. 1H-NMR (CDCl3, 500 MHz): δ 1.26 (s, 3H), 1.50-1.61 (m, 3H), 1.671.71 (m, 2H), 1.79-1.82 (d, 1H), 2.25-2.28 (d, 1H), 2.39 (s, 3H), 2.74-2.77 (d, 1H),
3.16-3.20 (d, 1H), 5.19 (s, 1H), 6.16 (s, 1H), 7.02-7.46 (m, 9).
(4-fluorophenyl)(1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1Hbenzo[f]indazol-5-yl)methanol

(11cc):

From

10c

using

4-

fluorophenylmagnesiumbromide (2.0M in Et2O). Flash column mobile phase 15% EtOAc/hexanes. Yield = 69%. TLC Rf = 0.26 (30% EtOAc/hexanes). HRMS
(DART-RTOF) m/z: [M+H]+ Calcd for C26H28FN2O2, 419.21293; found 419.20660.
1

H-NMR (CDCl3, 500 MHz): δ 1.26 (s, 3H), 1.56-1.58 (m, 2H), 1.66-1.70 (m, 2H),

1.79-1.82 (m, 1H), 2.25-2.28 (m, 1H), 2.37-2.40 (m, 1H), 2.73-2.76 (d, 1H), 3.173.20 (d, 1H), 3.85 (s, 3H), 5.20 (d, 1H), 6.11 (s, 1H), 6.96-7.06 (m, 4H), 7.30-7.44
(m, 5H).
General Procedure for R2 = 2,3-difluoroanisolyl 2˚OH analogues: A solution
of 5-Bromo-2,3-difluoroanisole (4.6 mmol) in THF (10 mL) was cooled to -78 °C,
to which a commercially available solution of 1.9 M t-BuLi in pentanes (4.6 mmol,
2.9 mL) was added dropwise via syringe. The reaction was stirred for 20 min at 78 °C, raised to 0 °C for 5-10 min until the solution transitioned from pale yellow
to dark yellow-green, and then was immediately cooled back to -78 °C for 5 min.
A solution of 10 (0.46 mmol) in THF (2 mL) was added dropwise via canula, and
the reaction was stirred at -78 °C for 1 h. The reaction was quenched with IPA,
poured into a separatory funnel containing saturated NH4Cl, and extracted three
times with EtOAc. The organic phase was washed with water and brine, dried
over anhydrous MgSO4, filtered, and concentrated in vacuo. Purification of the
crude product was accomplished using flash chromatography to give a white
solid.
(3,4-difluoro-5-methoxyphenyl)(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8hexahydro-1H-benzo[f]indazol-5-yl)methanol

(11ad):

From

10a

using

commercially available 5-bromo-2,3-difluoroanisole. Flash column mobile phase
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– 30% EtOAc/hexanes. Yield = 61.9 %. TLC Rf = 0.26 (25% EtOAc/hexanes). 1HNMR (CDCl3, 300 MHz) δ 1.26 (s, 3H), 1.54-1.57 (m, 1H), 1.64-1.72 (m, 1H),
1.82-1.86 (m, 2H), 2,28-2.46 (m, 3H), 2.72-2.77 (d, 1H), 3.17-3.22 (d, 1H), 3.92
(s, 3H), 5.12 (s, 1H), 6.12 (s, 1H), 6.72-6.80 (m, 2H), 7.15-7.21 (m, 2H), 7.457.54 (m, 3H).
(3,4-difluoro-5-methoxyphenyl)(4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro1H-benzo[f]indazol-5-yl)methanol (11bd): From 10b using commercially
available 5-bromo-2,3-difluoroanisole. Flash column mobile phase - 10%
EtOAc/hexanes. Yield = 76.7 %. TLC Rf = 0.22 (25% EtOAc/hexanes). HRMS
(DART-RTOF) m/z:

[M+H]+ Calcd for C27H29F2N2O2, 451.21916; found

451.21790. 1H-NMR (CDCl3, 500 MHz) δ 1.25 (m, 3H), 1.37-1.50 (m, 2H), 1.541.65 (m, 2H), 1.76-1.79 (d, 1H), 2.04 (s, 3H), 2.26-2.29 (d, 1H), 2.72-2.75 (d, 1H),
3.14-3.17 (d, 1H), 3.88 (s, 3H), 5.10 (s, 1H), 6.16 (s, 1H), 6.72-6.78 (m, 2H),
7.24-7.46 (m, 6H).
(3,4-difluoro-5-methoxyphenyl)(1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8hexahydro-1H-benzo[f]indazol-5-yl)methanol

(11cd):

From

10c

using

commercially available 5-bromo-2,3-difluoroanisole. Flash column mobile phase 15% EtOAc/hexanes. Yield = 71.4 %. TLC Rf = 0.16 (30% EtOAc/hexanes).
HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C27H29F2N2O3, 467.21408; found
467.21488. 1H-NMR (CDCl3, 500 MHz) δ 1.26 (s, 3H), 1.52-1.56 (m, 2H), 1.661.69 (m, 2H), 1.80-1.84 (m, 2H), 2.26-2.29 (m, 1H), 2.73-2.76 (d, 1H), 3.15-3.18
(d, 1H), 3.85 (s, 3H), 3.91 (s, 3H), 5.12 (s, 1H), 6.11 (s, 1H), 6.72-6.79 (m, 2H),
6.96-6.99 (m, 2H), 7.37-7.44 (m, 3H).
General Procedure for R2 = thiophenyl 2˚OH analogues: A solution of 3bromothiophene (0.6 mL, 6.4 mmol) in THF (10 mL) was cooled to -78 °C, to
which a commercially available solution of 1.9 M t-BuLi in pentanes (6.8 mL, 12.8
mmol) was added dropwise via syringe. After the reaction stirred for 30 min at 78 °C, a solution of 10 (6.4 mmol) in THF (2 mL) was added dropwise via canula,
and the reaction was allowed to gradually warm to room temperature over the
course of 1.5 h. After returning the reaction to -78 °C, the reaction was quenched
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with IPA, poured into a separatory funnel containing saturated NH4Cl, and
extracted three times with EtOAc. The organic phase was washed with water and
brine, dried over anhydrous MgSO4, filtered, and concentrated in vacuo.
Purification of the crude product was accomplished using flash chromatography
(10% EtOAc/hexanes) to give a white solid.
(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5yl)(thiophen-3-yl)methanol (11ae): From 10a using commercially available 3bromothiophene. Flash column mobile phase – 10% EtOAc/hexanes. Yield =
35.8%. TLC Rf = 0.26 (25% EtOAc/hexanes). 1H-NMR (CDCl3, 500 MHz) δ 1.24
(s, 3H), 1.65-1.93 (m, 5H), 2.27-2.48 (m, 2H), 2.67-2.72 (d, 1H), 3.08-3.15 (d,
1H), 5.24 (s, 1H), 6.12 (s, 1H), 6.94-6.99 (m, 1H), 7.12-7.24 (m, 3H), 7.30-7.33
(m, 1H), 7.43-7.48 (m, 3H).
(4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5yl)(thiophen-3-yl)methanol (11be): From 10b using commercially available 3bromothiophene. Flash column mobile phase – 10% EtOAc/hexanes. Yield =
35.8%. TLC Rf = 0.26 (25% EtOAc/hexanes). HRMS (DART-RTOF) m/z: [M+H]+
Calcd for C24H27N2OS, 391.18386; found 391.13976. 1H-NMR (CDCl3, 500 MHz)
δ 1.23 (s, 3H), 1.62-1.91 (m, 6H), 2.26-2.31 (m, 1H), 2.40 (s, 3H), 2.67-2.72 (m,
1H), 3.06-3.14 (m, 1H), 5.39 (s, 1H), 6.16 (s, 1H), 6.95-7.43 (m, 8H).
(1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol5-yl)(thiophen-3-yl)methanol (11ce): From 10c using commercially available 3bromothiophene. Flash column mobile phase – 15% EtOAc/hexanes. Yield =
79.5%. TLC Rf = 0.17 (30% EtOAc/hexanes). HRMS (ESI-RTOF) m/z: [M+H]+
Calcd for C24H27N2O2S, 407.1787; found 407.1720. 1H-NMR (CDCl3, 500 MHz) δ
1.26 (m, 4H), 1.62-1.72 (m, 2H), 1.77-1.85 (m, 2H), 2.27-2.41 (m, 2H), 2.69-2.72
(d, 1H), 3.12-3.15 (d, 1H), 3.85 (s, 3H), 5.25 (s, 1H), 6.12 (s, 1H), 6.96-7.40 (m,
8H).
3-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol5-yl)-3-hydroxypropanenitrile (11af): A commercially available solution of 1.7 M
t-BuLi in pentanes (0.9 mL, 1.53 mmol) was transferred to a round bottom flask
113

containing THF (2 mL) and cooled to -78 °C. A solution of ACN (80 µL) in THF (2
mL) was added dropwise at -78 °C. Following addition, a solution of 10a (400
mg, 1.3 mmol) in THF (2 mL) was added dropwise via canula, and the reaction
was stirred at -78 °C for 1 h. The reaction was quenched with saturated NH 4Cl,
acidified to a pH of 7 via dropwise addition of 0.5 M HCl, and extracted three
times with diethyl ether. The organic phase was washed with water and brine,
dried over anhydrous MgSO4, filtered, and concentrated in vacuo. Purification of
the crude product was accomplished using flash chromatography (25%
EtOAc/hexanes) to give a white solid. Yield = 45.5%. TLC R f = 0.14 (25%
EtOAc/hexanes). HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C21H23FN3O,
352.18197; found 352.18293. 1H-NMR (CDCl3, 500 MHz) δ 1.04-1.13 (s, 3H),
1.25-1.46 (m, 2H), 1.61-1.71 (m, 2H), 1.78-1.97 (m, 2H), 2.30-2.42 (m, 2H), 2.472.72 (m, 3H), 2.93-3.21 (d, 1H), 4.16-4.40 (m, 1H), 6.12 (s, 1H), 7.14-7.44 (m,
5H).
General method for the synthesis of intermediate 12: A solution of the
appropriate 2˚-OH precursor (11) in dichloromethane was transferred dropwise
via canula to a suspension of pyridinium chlorochromate (1.5 molar equivalents
to compound being oxidized) and freshly activated 4 Å molecular sieves (an
equivalent weight to compound being oxidized) in dichloromethane. The reaction
was stirred at room temperature until complete conversion was observed by TLC
analysis (reaction times varied from 1-7 h). Upon complete conversion, the
reaction mixture was immediately loaded onto a prepared florisil column (packed
DCM slurry) and subjected to purification via flash chromatography (100% DCM
flush) to give ketone 12 in sufficient purity to move forward with the synthesis.
3-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol5-yl)-3-hydroxybutanenitrile (12af): White solid obtained from 11af with PCC
as the oxidizing agent. Yield = 16%. TLC Rf = 0.11 (30% EtOAc/hexanes). HRMS
(DART-RTOF) m/z: [M+H]+ Calcd for C21H21FN3O, 350.16632; found 350.16529.
1

H-NMR (CDCl3, 500 MHz) δ 1.20 (s, 3H), 1.45-1.49 (m, 2H), 1.82-1.87 (t, 2H),
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1.93-1.97 (d, 1H), 2.32-2.44 (m, 3H), 2.74-2.77 (d, 1H), 2.82-2.88 (m, 2H), 3.533.61 (s, 2H), 6.15 (s, 1H), 7.14-7.44 (m, 5H).
General method for the synthesis of compound 13 analogues: The
appropriate ketone precursor (12) was dissolved in diethyl ether and cooled to 40 °C, and a commercially available solution of MeLi (1.9 M, 10 equivalents to
ketone starting material) was added dropwise via syringe. The reaction was
stirred under argon at -40° for 45 min. The reaction was quenched with IPA (10
equivalents to MeLi added), poured into a separatory funnel containing saturated
NH4Cl, and extracted with EtOAc. The organic phase was washed with water and
brine, dried over anhydrous MgSO4, filtered, and concentrated in vacuo.
Purification was accomplished using flash chromatography (see each entry for
respective column conditions)
2-((4aR)-4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5yl)propan-2-ol (13ba): From appropriate ketone 12 using commercially available
MeLi (1.9 M in Et2O) to give a white solid in 55% yield. Flash column mobile
phase - 20% EtOAc/hexanes. TLC Rf = 0.17 (25% EtOAc/hexanes). HRMS (ESIRTOF) m/z: [M+H]+ Calcd for C22H29N2O, 337.2274; found 337.2200. 1H-NMR
(CDCl3, 500 MHz) δ 1.19 (s, 3H), 1.33-1.37 (s, 8H), 1.38-1.39 (d, 1H), 1.66-1.69
(d, 1H), 1.77-1.80 (dt, 1H), 1.84-1.87 (dt, 1H), 2.31 (m, 1H), 2.39 (s, 3H), 2.732.76 (d, 1H), 3.53-3.57 (d, 1H), 6.16 (s, 1H) 7.24-7.25 (d, 2H), 7.35-7.38 (d, 2H),
7.40 (s, 1H).
1-((4aR)-4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5yl)-1-phenylethan-1-ol (13bb): From appropriate ketone 12 using commercially
available MeLi (1.9 M in Et2O) to give a white solid in 82% yield. Flash column
mobile phase - 15% EtOAc/hexanes. TLC Rf = 0.27 (30% EtOAc/hexanes).
HRMS (ESI-RTOF) m/z: [M+H]+ Calcd for C27H31N2O, 399.2430; found 399.2368.
); 1H-NMR (CDCl3, 500 MHz) δ 1.27 (s, 3H), 1.62-1.66 (m, 2H), 1.68 (s, 3H),
1.74-1.79 (m, 2H), 2.04-2.07 (d, 1H), 2.24-2.28 (d, 1H), 2.33-2.40 (m, 4H), 2.602.63 (d, 1H), 3.10-3.13 (d, 1H), 6.14 (s, 1H), 7.23-7.29 (m, 4H), 7.33-7.36 (m,
4H), 7.49-7.52 (m, 2H).
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1-(4-fluorophenyl)-1-((4aR)-4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1Hbenzo[f]indazol-5-yl)ethan-1-ol (13bc): From appropriate ketone 12 using
commercially available MeLi (1.9 M in Et2O) to give a white solid in 80% yield.
Flash column mobile phase - 15% EtOAc/hexanes. TLC Rf = 0.25 (30%
EtOAc/hexanes). HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C27H30FN2O,
417.23367; found 417.23232. 1H-NMR (CDCl3, 500 MHz) δ 1.26 (s, 3H), 1.601.63 (m, 3H), 1.66 (s, 3H), 1.75-1.79 (d, 1H), 1.99-2.02 (d, 1H), 2.24-2.27 (d, 1H),
2.39 (s, 3H), 2.60-2.63 (d, 1H), 3.12-3.15 (d, 1H), 5.30 (s, 1H), 6.14 (s, 1H), 7.017.48 (m, 9H).
1-(3,4-difluoro-5-methoxyphenyl)-1-((4aR)-4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8hexahydro-1H-benzo[f]indazol-5-yl)ethan-1-ol

(13bd):

From

appropriate

ketone 12 using commercially available MeLi (1.9 M in Et2O) to give a white solid
in 94% yield. Flash column mobile phase - 10% EtOAc/hexanes. TLC Rf = 0.19
(30% EtOAc/hexanes). HRMS (ESI-RTOF) m/z: [M+H]+ Calcd for C28H31F2N2O2,
465.2348; found 465.2283. 1H-NMR (CDCl3, 500 MHz) δ 1.22-1.35 (m, 6H), 1.581.62 (m, 4H), 1.79-1.83 (d, 1H), 1.96-1.99 (d, 1H), 2.25-2.28 (d, 1H), 2.34-2.44
(s, 3H), 2.57-2.61 (d, 1H), 3.05-3.08 (d, 1H), 3.91-3.96 (s, 3H), 6.15 (s, 1H), 6.876.92 (m, 2H), 7.23-7.30 (m, 4H), 7.36 (s, 1H).
1-((4aR)-4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5yl)-1-(thiophen-2-yl)ethan-1-ol (13be): From appropriate ketone 12 using
commercially available MeLi (1.9 M in Et2O) to give a white solid in 76% yield.
Flash column mobile phase - 10% EtOAc/hexanes. TLC Rf = 0.28 (25%
EtOAc/hexanes). HRMS (ESI-RTOF) m/z: [M+H]+ Calcd for C25H29N2OS,
405.1995; found 405.1899. 1H-NMR (CDCl3, 500 MHz) δ 1.25 (s, 3H), 1.40-1.41
(d, 1H), 1.57-1.59 (d, 1H), 1.65 (s, 3H), 1.69-1.70 (d, 2H), 1.76-1.78 (d, 1H),
2.03-2.06 (d, 1H), 2.26-2.28 (d, 1H), 2.39 (s, 3H), 2.66-2.69 (d, 1H), 3.22-3.25 (d,
1H), 6.15 (s, 1H), 7.12-7.37 (m, 8H).
2-((4aR)-1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1Hbenzo[f]indazol-5-yl)propan-2-ol (13ca): From appropriate ketone 12 using
commercially available MeLi (1.9 M in Et2O) to give a white solid in 58% yield.
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Flash column mobile phase - 25% EtOAc/hexanes. TLC Rf = 0.08 (30%
EtOAc/hexanes). HRMS (ESI-RTOF) m/z: [M+H]+ Calcd for C22H29N2O2,
353.2223; found 353.2184. 1H-NMR (CDCl3, 500 MHz) δ 1.19 (s, 3H) 1.30-1.38
(d, 6H), 1.48-1.55 (m, 1H), 1.66-1.69 (d, 1H), 1.76-1.87 (dd, 2H), 2.27-2.37 (m,
3H), 2.73-2.76 (d, 1H), 3.53-3.57 (d, 1H), 3.85 (s, 3H), 6.11 (s, 1H) 6.95-7.41 (m,
5H).
1-((4aR)-1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1Hbenzo[f]indazol-5-yl)-1-phenylethan-1-ol (13cb): From appropriate ketone 12
using commercially available MeLi (1.9 M in Et2O) to give a beige solid in 100%
yield. Flash column mobile phase - 10% EtOAc/hexanes. TLC Rf = 0.20 (30%
EtOAc/hexanes). HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C27H31N2O2,
415.23800; found 415.23680. 1H-NMR (CDCl3, 500 MHz) δ 1.27 (s, 3H), 1.551.63 (m, 3H), 1.68 (s, 3H), 1.75-1.77 (m, 1H), 2.04-2.07 (m, 1H), 2.23-2.26 (m,
1H), 2.33-2.38 (m, 1H), 2.60-2.63 (d, 1H), 3.10-3.13 (d, 1H), 3.84 (s, 3H), 6.08 (s,
1H), 6.95-7.51 (m, 10H).
1-(4-fluorophenyl)-1-((4aR)-1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8hexahydro-1H-benzo[f]indazol-5-yl)ethan-1-ol

(13cc):

From

appropriate

ketone 12 using commercially available MeLi (1.9 M in Et2O) to give a white solid
in 49% yield. Flash column mobile phase - 20% EtOAc/hexanes. TLC Rf = 0.28
(30%

EtOAc/hexanes).

HRMS

(DART-RTOF)

m/z:

[M+H]+

Calcd

for

1

C27H30FN2O2, 433.22858; found 433.22897. H-NMR (CDCl3, 300 MHz) δ 1.25
(s, 3H), 1.53-1.62 (m, 2H), 1.67 (s, 3H), 1.73-1.78 (m, 1H), 1.99-2.02 (d, 1H),
2.24-2.36 (m, 3H), 2.60-2.63 (d, 1H), 3.12-3.15 (d, 1H), 3.85 (s, 3H), 6.09 (s, 1H),
6.95-7.49 (m, 9H).
1-(3,4-difluoro-5-methoxyphenyl)-1-((4aR)-1-(4-methoxyphenyl)-4a-methyl4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)ethan-1-ol

(13cd):

From

appropriate ketone 12 using commercially available MeLi (1.9 M in Et 2O) to give
a white solid in 65% yield. Flash column mobile phase - 15% EtOAc/hexanes.
TLC Rf = 0.13 (30% EtOAc/hexanes). HRMS (DART-RTOF) m/z: [M+H]+ Calcd
for C27H30FN2O2, 433.22858; found 433.22897. 1H-NMR (CDCl3, 500 MHz) δ
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1.26 (s, 3H), 1.60-1.67 (m, 6H) 1.79-1.82(d, 1H), 1.96-1.99 (d, 1H), 2.24-2.39 (m,
2H), 2.57-2.60 (d, 1H), 3.05-3.08 (d, 1H), 3.85 (s, 3H), 3.91 (s, 3H), 6.10 (s, 1H),
6.87-7.01 (m, 4H), 7.32-7.45 (m, 3H).
1-((4aR)-1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1Hbenzo[f]indazol-5-yl)-1-(thiophen-2-yl)ethan-1-ol (13ce): From appropriate
ketone 12 using commercially available MeLi (1.9 M in Et2O) to give a white solid
in 48% yield. Flash column mobile phase - 15% EtOAc/hexanes. TLC Rf = 0.16
(30%

EtOAc/hexanes).

HRMS

(ESI-RTOF)

m/z:

[M+H]+

Calcd

for

C25H29N2O2S, 421.1944; found 421.1907. 1H-NMR (CDCl3, 500 MHz) δ1.25
(s, 3H), 1.59-1.65 (m, 2H), 1.68 (s, 3H), 1.73-1.78 (m, 2H), 2.03-2.06 (d, 1H),
2.25-2.36 (m, 2H), 2.65-2.69 (d, 1H), 3.22-3.25 (d, 1H), 3.84 (s, 3H), 6.10 (s, 1H),
6.94-7.40 (m, 8H)
2.5.2 Steroidal glucocorticoid synthetic procedure
The procedure used for the synthesis of all mercaptocoids was previously
reported with slight modifications of known methods.56 All reactions were done
under inert atmosphere using dry solvents unless otherwise stated. All chemicals
and solvents were purchased through VWR or Fisher Scientific and were reagent
grade. NMRs were taken on a Varian VNMRS 500 MHz.
General Procedure for R1 instillation: The appropriate steroid was stirred into
dichloromethane and the mixture was cooled to 0 °C. 7.5 molar equivalents of
diisopropylethylamine (DIPEA) was added to cold solution followed directly by
1.5 molar equivalents of mesylchloride (MsCl). The reaction was slowly warmed
to room temperature and stirred for 15 hours or until completion monitored
through TLC. Once the starting material was not visible on TLC, the reaction was
concentrated in vacuo. The resulting oil was then redissolved in dichloromethane
and washed with saturated bicarbonate. The water layer was then extracted with
dichloromethane. The organic layers were then combined and washed with brine
in triplicate. The organic layers were dried with MgSO4, filtered, and concentrated
to give a light brown crystalline solid as the mesylate of the steroid. The
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intermediate was carried crude through the next reaction. The steroid mesylate
was then dissolved in reagent grade acetone. 10 molar equivalents of potassium
carbonate were then added to the solution followed directly by 2 molar
equivalents of 2-mercaptobenzothiazole and the resulting mixture was refluxed
for 1 hour. One completion of the reaction monitored through TLC, the mixture
was filtered through a pad of silica and the filtrate was concentrated in vacuo to
give a white solid. The product was then purified by column chromatography
using 3:2 hexanes: ethyl acetate (Hex: EtOAc) to elute the product as a white
solid.
(9R,10S,11S,13S,16R,17R)-17-(2-(benzo[d]thiazol-2-ylthio)acetyl)-9-fluoro11,17-dihydroxy-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17dodecahydro-3H-cyclopenta[a]phenanthren-3-one

(2a):

From

dexamethasone using 2-mercaptobenzothiazole to give a white solid in 70%
yield. Flash column mobile phase 40% EtOAc/hexanes TLC Rf = 0.20 (25%
EtOAc/hexanes 1H-NMR (CDCl3, 500 MHz) δ 0.91 (d, 3H), 1.03 (s, 3H), 1.241.32 (m, 2H), 1.47 (dd, 1H), 1.56 (s, 3H), 1.67 (m, 3H), 1.84-1.89 (dt, 1H), 2.332.45 (m, 3H), 2.59-2.66 (m, 1H), 2.77-2.81 (dt, 1H), 3.14-3.16 (d, 1H), 3.12-3.18
(m, 1H), 4.39-4.45 (m, 1H), 5.03-5.07 (d, 1H), 6.02 (s, 1H), 6.13 (s, 1H), 6.336.35 (dd, 1H), 7.19-7.23 (d, 1H), 7.29-7.31 (ddd, 1H), 7.39-7.41 (ddd, 1H), 7.707.78 (dd, 2H)

13

C-NMR (CDCl3, 500 MHz) δ 15.59, 17.33, 23.01, 23.06, 27.28,

31.08, 32.48, 34.18, 34.33, 37.96, 47.36, 48.13, 48.31, 72.47, 92.14, 120.78,
121.24, 124.81, 125.14, 125.14, 129.03, 134.91, 151.81, 167.18, 186.51, 206.59
(9R,10S,11S,13S,16S,17R)-17-(2-(benzo[d]thiazol-2-ylthio)acetyl)-9-fluoro11,17-dihydroxy-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17dodecahydro-3H-cyclopenta[a]phenanthren-3-one

(2b):

From

Betamethasone using 2-mercaptobenzothiazole to give a white solid in 68%
yield. Flash column mobile phase 40% EtOAc/hexanes TLC Rf = 0.24 (25%
EtOAc/hexanes 1H-NMR (CDCl3, 500 MHz) δ 0.96 (s, 3H), 1.13-1.23 (m, 3H),
1.39-1.41 (m, 3H), 1.45 (s, 3H), 1.60-1.64 (m, 2H), 1.81-1.95 (m, 3H), 2.00-2.09
(m, 2H) 2.15-2.20 (m, 1H) 2.20-2.30 (m, 1H), 2.23-2.40 (m, 2H), 2.43-2.53 (m,
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2H), 2.69-2.80 (m, 1H), 3.35-3.45 (d, 1H), 4.45-4.55 (m, 1H), 5.06-5.14 (d,1H),
5.70 (s, 1H) 7.30-7.36 (t, 1H), 7.39-7.44 (t, 1H), 7.72-7.76 (d, 1H), 7.80-7.84 (d,
1H)

13

C-NMR (CDCl3, 500 MHz) δ 14.18, 17.48, 19.97, 23.01, 27.56, 31.12,

33.70, 35.12, 38.72, 39.20, 43.39, 46.81, 47.69, 48.29, 52.08, 60.40, 68.50,
72.17, 72.47, 90.28, 91.08, 120.43, 121.33, 122.31, 124.97, 126.68, 129.75,
152.40, 166.47, 186.69, 206.34
(10R,11S,13S,17R)-17-(2-(benzo[d]thiazol-2-ylthio)acetyl)-11,17-dihydroxy10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3Hcyclopenta[a]phenanthren-3-one

(2c):

From

prednisolone

using

2-

mercaptobenzothiazole to give a white solid in 74% yield. Flash column mobile
phase 40% EtOAc/hexanes TLC Rf = 0.22 (25% EtOAc/hexanes 1H NMR (500
MHz, Chloroform-d) δ 7.75 (s, 1H), 7.70 (s, 1H), 7.39 (s, 1H), 7.28 (s, 2H), 6.27
(s, 1H), 6.01 (s, 1H), 4.97 (d, J = 15.5 Hz, 1H), 4.50 (s, 1H), 3.41 (s, 1H), 2.79 (s,
1H), 2.61 (s, 2H), 2.53 (s, 1H), 2.35 (s, 2H), 2.15 (d, J = 4.7 Hz, 7H), 1.87 (s, 2H),
1.60 (d, J = 40.8 Hz, 2H), 1.45 (s, 4H), 1.43 – 1.37 (m, 1H), 1.23 (s, 6H), 1.12 (s,
2H), 0.96 (s, 3H).

13

C NMR (126 MHz, Chloroform-d) δ 206.40, 186.66, 170.38,

167.71, 156.39, 127.79, 126.55, 125.00, 122.34, 121.34, 120.39, 90.98, 70.32,
55.32, 51.45, 47.03, 44.13, 40.42, 37.29, 34.76, 33.94, 32.06, 31.35, 24.07,
21.08, 17.59.
(6S,9R,10S,11S,13S,16R,17R)-17-(2-(benzo[d]thiazol-2-ylthio)acetyl)-6,9difluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17dodecahydro-3H-cyclopenta[a]phenanthren-3-one (2d): From flumetasone
using 2-mercaptobenzothiazole to give a white solid in 66% yield. Flash column
mobile phase 40% EtOAc/hexanes TLC Rf = 0.21 (25% EtOAc/hexanes 1H NMR
(500 MHz, Chloroform-d) δ 7.88 (s, 1H), 7.73 (s, 1H), 7.45 (s, 1H), 7.35 (s, 1H),
7.14 (d, J = 11.5 Hz, 1H), 6.43 (s, 1H), 6.37 (d, J = 12.0 Hz, 1H), 5.37 (d, J = 48.8
Hz, 1H), 5.12 (s, 1H), 4.42 (s, 1H), 3.38 (s, 1H), 3.18 (s, 1H), 2.77 (s, 1H), 2.47
(d, J = 54.9 Hz, 2H), 2.27 (s, 1H), 2.17 (s, 1H), 1.75 (s, 1H), 1.59 (s, 1H), 1.54 (s,
3H), 1.31 (d, J = 16.1 Hz, 1H), 1.25 (d, J = 1.4 Hz, 1H), 1.03 (s, 2H), 0.93 (s, 3H).
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(6aR,7S,8aS,8bS)-8b-(2-(benzo[d]thiazol-2-ylthio)acetyl)-7-hydroxy-6a,8adimethyl-10-propyl-1,2,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-4Hnaphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4-one (2e): From budesonide using
2-mercaptobenzothiazole to give a white solid in 70% yield. Flash column mobile
phase 40% EtOAc/hexanes TLC Rf = 0.20 (25% EtOAc/hexanes 1H NMR (500
MHz, Chloroform-d) δ 7.77 (d, J = 24.1 Hz, 2H), 7.39 (s, 1H), 7.28 (s, 2H), 6.24
(s, 1H), 6.00 (s, 1H), 5.21 (s, 1H), 4.91 (s, 1H), 4.74 (s, 1H), 4.59 (s, 3H), 4.40 (s,
1H), 2.53 (s, 1H), 2.32 (s, 1H), 2.15 (s, 2H), 2.03 (s, 3H), 1.84 – 1.51 (m, 5H),
1.39 (s, 5H), 1.13 (s, 2H), 1.04 (s, 1H), 0.99 (s, 2H), 0.93 (d, J = 12.3 Hz, 3H).
(6aR,7S,8aS,8bS)-8b-(2-(benzo[d]thiazol-2-ylthio)acetyl)-7-hydroxy6a,8a,10,10-tetramethyl-1,2,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-4Hnaphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4-one (2f): From desonide using 2mercaptobenzothiazole to give a white solid in 66% yield. Flash column mobile
phase 40% EtOAc/hexanes TLC Rf = 0.21 (25% EtOAc/hexanes 1H NMR (500
MHz, Chloroform-d) δ 7.86 (s, 2H), 7.76 (s, 2H), 7.43 (s, 2H), 7.33 (s, 2H), 7.26
(s, 3H), 6.30 (s, 2H), 6.02 (s, 2H), 5.04 (s, 2H), 4.68 (s, 2H), 4.60 (s, 2H), 4.55 (s,
2H), 2.54 (s, 3H), 2.34 (ddd, J = 13.5, 4.9, 2.1 Hz, 2H), 2.16 (s, 13H), 1.74 (s,
3H), 1.60 (s, 5H), 1.46 (s, 12H), 1.25 (s, 1H), 1.22 (s, 3H), 1.14 (s, 8H), 0.98 (s,
6H).
Procedure for R2 instillation: The appropriate benzothiazole steroid was
dissolved in dichloromethane and the solution was cooled to 0 °C. To the cooled
solution, 1.3 molar equivalents of 4-dimethylaminopyridine (DMAP) was added
directly followed by the addition of 1.1 molar equivalents of furoyl chloride. The
reaction was slowly warmed to room temperature and monitored by TLC for
completion. Once there was no change was seen on the TLC plate after 24 hours
of stirring the reaction was diluted with dichloromethane and washed in triplicate
with brine, dried with MgSO4, and filtered. The filtrate was concentrated in vacuo
and the crude product was purified by column chromatography using 99:1
dichloromethane: methanol (CH2Cl2:MeOH) to elute the product as a white solid.
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(9R,10S,11S,13S,16R,17R)-17-(2-(benzo[d]thiazol-2-ylthio)acetyl)-9-fluoro11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate (3a):
From 3a using furoyl chloride to give a white solid in 34% yield. Flash column
mobile phase 1% CHCl3/methanol TLC Rf = 0.11 (25% EtOAc/hexanes 1H NMR
(500 MHz, Chloroform-d) δ 7.80 – 7.69 (m, 2H), 7.59 (dd, J = 1.7, 0.8 Hz, 1H),
7.39 (dtd, J = 8.3, 7.3, 6.8, 1.3 Hz, 1H), 7.28 (ddd, J = 8.2, 7.3, 1.2 Hz, 3H), 7.25
– 7.15 (m, 2H), 6.51 (dd, J = 3.5, 1.7 Hz, 1H), 6.35 (ddd, J = 13.8, 10.1, 1.8 Hz,
1H), 6.14 (dt, J = 14.1, 1.7 Hz, 1H), 4.51 – 4.39 (m, 3H), 3.51 (ddd, J = 10.6, 6.9,
3.5 Hz, 1H), 2.70 – 2.56 (m, 2H), 2.51 – 2.32 (m, 4H), 1.93 – 1.82 (m, 4H), 1.67 –
1.51 (m, 5H), 1.41 – 1.28 (m, 2H), 1.28 – 1.22 (m, 1H), 1.17 (s, 3H), 1.04 – 0.99
(m, 4H), 0.93 – 0.86 (m, 1H).

13

C NMR (126 MHz, Chloroform-d) δ 186.39,

165.95, 165.66, 158.05, 152.71, 151.68, 147.46, 143.20, 135.61, 130.01, 126.41,
126.03, 125.25, 124.83, 124.40, 121.25, 121.15, 119.47, 112.17, 100.77, 72.11,
71.80, 48.63, 48.17, 47.99, 43.73, 37.27, 36.04, 34.07, 33.91, 33.63, 30.91,
27.32, 23.03, 22.98, 16.84, 16.70.
(9R,10S,11S,13S,16S,17R)-17-(2-(benzo[d]thiazol-2-ylthio)acetyl)-9-fluoro11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17dodecahydro-3H-cyclopenta[a]phenanthren-17-yl

cyclopenta-1,3-diene-1-

carboxylate (3b): From 2b using furoyl chloride to give a white solid in 34%
yield. Flash column mobile phase 1% CHCl3/methanol TLC Rf = 0.12 (25%
EtOAc/hexanes 1H-NMR (CDCl3, 500 MHz) δ 1.27 (s, 3H), 1.55-1.63 (m, 3H),
1.68 (s, 3H), 1.75-1.77 (m, 1H), 2.04-2.07 (m, 1H), 2.23-2.26 (m, 1H), 2.33-2.38
(m, 1H), 2.60-2.63 (d, 1H), 3.10-3.13 (d, 1H), 3.84 (s, 3H), 6.08 (s, 1H), 6.95-7.51
(m, 10H). 1H NMR (500 MHz, Chloroform-d) δ 8.02 – 7.94 (m, 2H), 7.75 – 7.69
(m, 2H), 7.65 – 7.54 (m, 1H), 7.51 – 7.41 (m, 2H), 7.41 – 7.32 (m, 1H), 7.27 (ddd,
J = 8.2, 7.2, 1.1 Hz, 1H), 5.72 (d, J = 1.6 Hz, 1H), 4.63 – 4.55 (m, 2H), 4.38 (d, J
= 17.0 Hz, 1H), 3.12 (ddd, J = 16.2, 11.3, 2.3 Hz, 1H), 2.52 (ddd, J = 18.8, 11.0,
4.9 Hz, 2H), 2.45 – 2.32 (m, 2H), 2.31 – 2.21 (m, 2H), 2.15 (tdd, J = 13.9, 9.4, 3.3
Hz, 2H), 2.09 – 1.90 (m, 3H), 1.90 – 1.71 (m, 3H), 1.48 (s, 4H), 1.25 (s, 1H), 1.22
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– 1.11 (m, 3H), 1.10 (s, 2H).

13

C NMR (126 MHz, Chloroform-d) δ 206.34,

186.59, 152.14, 129.84, 126.71, 126.48, 125.13, 124.99, 124.93, 122.36, 121.34,
120.42, 90.30, 72.55, 72.24, 68.57, 55.99, 52.09, 48.25, 48.20, 47.57, 43.38,
40.59, 39.19, 38.39, 37.68, 35.13, 35.08, 34.84, 33.85, 33.80, 33.69, 32.66,
32.11, 31.50, 31.10, 30.92, 27.53, 23.85, 23.01, 22.97, 21.10, 19.98, 17.75,
17.53.
(10R,11S,13S,17R)-17-(2-(benzo[d]thiazol-2-ylthio)acetyl)-11-hydroxy-10,13dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3Hcyclopenta[a]phenanthren-17-yl furan-2-carboxylate (3c): From 2c using
furoyl chloride to give a white solid in 30% yield. . Flash column mobile phase 1%
CHCl3/methanol TLC Rf = 0.10 (25% EtOAc/hexanes). 1H NMR (500 MHz,
Chloroform-d) δ 7.77 (s, 2H), 7.59 (s, 2H), 7.40 (d, J = 8.4 Hz, 2H), 7.21 (s, 2H),
6.51 (d, J = 5.2 Hz, 2H), 6.37 (d, J = 10.1 Hz, 2H), 6.14 (d, J = 13.7 Hz, 2H), 5.04
(d, J = 15.1 Hz, 1H), 4.52 – 4.43 (m, 5H), 3.52 (d, J = 6.9 Hz, 2H), 3.06 (d, J =
15.1 Hz, 1H), 2.66 – 2.58 (m, 4H), 2.43 (s, 2H), 2.39 (s, 3H), 1.87 (s, 3H), 1.72
(s, 2H), 1.38 (s, 1H), 1.18 (s, 5H), 1.02 (d, J = 9.0 Hz, 6H), 0.90 (d, J = 7.1 Hz,
2H).

13

C NMR (126 MHz, Chloroform-d) δ 151.57, 147.46, 130.05, 126.03,

125.28, 124.40, 121.24, 121.16, 119.47, 112.18, 34.08, 33.92, 30.91, 23.02,
22.98, 16.85, 16.71.
(6S,9R,10S,11S,13S,16R,17R)-17-(2-(benzo[d]thiazol-2-ylthio)acetyl)-6,9difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren17-yl cyclopenta-1,3-diene-1-carboxylate (3d): From 2d using furoyl chloride to
give a white solid in 34% yield. Flash column mobile phase 1% CHCl 3/methanol
TLC Rf = 0.11 (25% EtOAc/hexanes 1H NMR (500 MHz, Chloroform-d) δ 7.78 (dt,
J = 8.2, 0.9 Hz, 2H), 7.74 – 7.68 (m, 2H), 7.44 – 7.36 (m, 2H), 7.34 – 7.25 (m,
3H), 7.17 (dd, J = 10.2, 1.5 Hz, 2H), 6.44 (q, J = 1.6 Hz, 2H), 6.36 (dd, J = 10.2,
1.9 Hz, 2H), 5.44 (ddd, J = 11.7, 6.6, 1.9 Hz, 1H), 5.34 (ddd, J = 11.7, 6.6, 1.9
Hz, 1H), 5.04 (d, J = 15.1 Hz, 2H), 4.42 (ddd, J = 9.4, 4.0, 2.1 Hz, 2H), 3.21 –
3.11 (m, 3H), 3.08 (s, 1H), 2.76 (dt, J = 14.4, 3.5 Hz, 2H), 2.59 – 2.49 (m, 2H),
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2.49 – 2.34 (m, 3H), 2.33 – 2.25 (m, 3H), 1.86 – 1.65 (m, 5H), 1.54 (s, 7H), 1.53
– 1.45 (m, 2H), 1.32 (ddd, J = 12.0, 8.0, 3.9 Hz, 3H), 1.25 (d, J = 1.8 Hz, 2H),
1.03 (s, 6H), 0.91 (d, J = 7.1 Hz, 7H).
2.5.3 Cell culture and glucose-stimulated insulin secretion (GSIS)
Culture of 832/13 cells and measurements of insulin secretion have been
described (Hohmeier, Diabetes, 2000). Six-point dose-response curves were
used to generate EC50 and saturating concentrations of each steroid compound
(not shown). For GSIS, saturating concentrations of each commercial steroid or
N-arylpyrazole based steroid were used as indicated in the figure legends.
2.5.4 Luciferase assays
832/13 cells were grown in 24-well plates to 50% confluence and then transiently
transfected with 25 ng of indicated plasmid per well using TransFectin Lipid
Reagent (Bio-Rad) according to the manufacturer’s instructions. Cell lysis,
luciferase assays, and normalization to total protein content were carried out as
described previously (Burke, JBC, 2015).

2.6 Results
2.6.1 Non-steroidal glucocorticoids
Synthetic GCs were tested for their ability to reduce IL-1β-induced inflammation
(CCL2 assay - transrepression), and their propensity for enhancing transcription
of a synthetic GRE-containing promoter luciferase reporter gene (3xGRE assay transactivation). Compounds providing the desired dissociated profile reduce
inflammation with reduced transactivation compared to dexamethasone.
Unfortunately for most of the compounds that exhibit transrepression, they also
enhance transactivation presumably through direct binding of GR-GC complex to
the nuclear GRE, thereby enhancing the transcription of pro-inflammatory
cytokines. This increase in transactivation also seems to be influenced by GCs
whose sidegroup can participate in π-π interactions with a bound GR. Two of the
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compounds 11aa and 13aa synthesized and screened for their therapeutic profile
showed the desired activity. (Figure 23) CCL2 and 3xGRE assay data for all
tested compounds can be found in the chapter Appendix 2.8. Three different
sets of GC analogues with respect to the installed headgroup (R1) were tested for
biological activity, and the 4-fluorophenyl series was observed to have the
greatest dissociated profile. Transrepression commenced at nM and µM
concentrations with ~70% reduction in relative promoter activity for the higher
concentrations of fluorophenyl GCs. Compounds with the greatest observed
transrepression were those whose sidegroup (R2) possesses a delocalized
system of π-electrons (R2 = phenyl, 4-fluorophenyl, 1,2-difluoroanisolyl, and 3thiophenyl). The observed activity is likely a function of hydrophobic interactions
between GC and bound GR. GCs with R2 moieties of smaller (methyl-), and
larger (cyanomethyl-) steric bulk that do not bear any delocalized π-electrons
show a significant decrease in desired activity, suggesting that size of the R2
group has little influence on biological response – but rather that electronic
interactions between GC and GR are more impactful.
Within the 4-fluorophenyl headgroup compound series, transactivation was
increased again with analogues bearing an R2 moiety having delocalized system
of π-electrons. Transactivation is observed at GC concentrations ranging from
nM to µM, where there is differential activity between molecule sets 11 and 13
having the same sidegroup. The additional steric bulk around the alcohol
introduced by a methyl group in compound series 13 seems to enhance
transrepression but also has an upregulating influence on transactivation, which
makes series 13 less therapeutically valuable than the series 11 analogues. The
intermediate ketone series 12aa-12ag was tested for biological activity, but was
found to enhance transactivation more than transrepression, indicating the
alcohol group of series 11 and 13 analogues being important in influencing
transrepressive activity of these molecules. It seems that coordination of the
alcohol and/or an electron rich aromatic R2 group in the GR binding pocket elicit
a dissociated profile, unlike with the ketone intermediate; Therefore, intermediate
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Figure 23: Non-steroidal glucocorticoid scaffold analogue data
A: CCL2 gene transcription assay B: 3xGRE promoter assay C: GSIS insulin suppression
assay
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series 12 (excluding analogues 12aa-12ag) were not subjected to biological
testing.
Both 1-(4-methoxyphenyl) and 1-(4-methylphenyl) headgroup analogues did not
show a significant decrease in transrepression or an increase in transactivation,
except for compounds whose R2 moiety contains delocalized π-electrons. For
those compounds, transrepression was diminished only at ~µm concentrations,
and an increase in transactivation was only observed at high GC concentration
(≥µM). This difference in activity compared to the 4-fluorophenyl headgroup
series may be attributable to differential solubility between the analogues, being
that fluorinated drugs are known for their increased lipid-solubility making them
more easily transported throughout the cell.117 Data from the inflammatory
assays portend that compared to the R1 = 1-(4-methoxyphenyl)- / 1-(4methylphenyl)-GCs, the R1 = 1-(4-fluorophenyl) series would appear to have a
greater affinity for the hGR, or may just be more easily transported throughout
the cell due to solubility properties compared to the other GC analogues. Binding
affinity calculations (Appendix 2.8.7) for all tested compounds reveal similar
affinities to the hGR (5NFP) with an average binding affinity of -9.5 ±1.75
kcal/mol. This may suggest some of the observed differences in biological activity
for the R1 = 1-(4-fluorophenyl) series as being a function of bioavailability.
An increase in transactivation is an undesired effect of these drug candidates,
and this activity is enhanced in compounds containing an aromatic sidegroup
(R2); Although, the modeled binding patterns within the hGR between the R2
analogues are similar, the aromatic sidegroups may generate strong π-π
interactions not accounted for with a non-flexible receptor model, which may be
an important factor in enhancing transactivation. There is also an observable
trend in which series 13 compounds have a higher average affinity for the hGR
than series 11, which may explain why compounds 12 and 13 exhibit stronger
transactivating activity when compared to 2˚OH series 11. The differential activity
observed between compounds bearing different R1 headgroups as suggested
before may be attributable to differences in bioavailability, but when considering
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the binding features in the R1 = 1-(4-fluorophenyl) series, there is a hydrophilic
interaction with residue Ala605 in nearly all instances, especially among the
molecules conferring the desired therapeutic profile.
2.6.2 Steroidal glucocorticoids
The steroidal glucocorticoid scaffolds analogues were synthesized to study the
effect of structural modifications to the steroid ring structure attempting to find
molecules

possessing varying structure-activity relationships to

improve

therapeutic value of glucocorticoid drugs. 2-Mercaptobenzothiazole modifications
to the steroid ring structure were previously reported as having dissociating
activities separating transrepression from transactivation.56,
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However only

hydrocortisone was subjected to testing dissociating activities and the results
were quite promising. Due to hydrocortisone’s improved IL-6 inhibition as well as
inhibiting transactivation potential multiple more synthetic steroids were
subjected to derivatization with 2-mercaptobenzothiazole and 2-furoyl groups at
R1 and R2 respectively. (Figure 24)
The

synthetic

steroids

that

were

subjected

to

derivatization

were

dexamethasone, betamethasone, prednisolone, flumetasone, budesonide, and
desonide. They were chosen due to their wide use in medicinal chemistry and
well-known enhancers of transactivation activity properties. The compounds were
tested for their ability to suppress or activate transactivation coming from a
promoter with three copies of the census glucocorticoid-response element
(3xGRE) as well as the ability to repress IL-1β mediated increase in the CCL2
gene transcription. The gene expression of CCL2 causes macrophages, Tlymphocytes and monocytes to travel to sites of inflammation sites and is
increased in both β-cells and adipose tissue. All steroid backbones tested
showed the ability to repress IL-1β simulated CCL2 gene transcription
(Appendix

2.8.10)

with

flumetasone

displaying

the

most

favorable

transrepressive bioactivity. Increased transcription tested on the steroid
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Figure 24: Steroidal scaffold

backbone was also observed in the 3xGRE containing promoter construct. This
result of the increased transrepression and transactivation activity was expected
in the steroid backbones as a dissociated profile is sought upon derivatization. Of
all the steroid derivatives tested 3d and 3c displayed the most favorable profile
across all concentrations. (Figure 25)
The remaining derivatives that displayed positive results were 3a and 3b, they
showed the ability to repress the cytokine at 0.1nM by 45% and 55%
respectively.

The

first

derivatization

of

the

steroid

scaffold

with

2-

mercaptobenzothiazole proved to have a negative result when compared to the
steroid backbone in each GC tested (2a-2f) (Appendix 2.8) The second
derivatization with the 2-furoyl group saw the transrepressive ability of the
analogues improve across all steroid backbones tested (3a-3d). (Figure 26)
The dexamethasone and betamethasone derivatives 3a and 3b saw no
improvement over their original steroid backbone tested. Prednisolone saw a
greatly improved ability to repress the cytokine across all concentrations in
derivative 3c. The second derivative of flumetasone 3d was by far the best
candidate tested in the CCL2 assay, repressing over 65% of the response from
the cytokines at 0.1 nM. The inability for prednisolone to repress the activity of
the cytokine at low concentrations is unlike other steroid backbones tested. It
could be hypothesized the C-16 methylation can prove vital to the activity,
because prednisolone is the one backbone tested with the absence of a methyl
group at C-16. There is a need for a further study with only a 2-furoyl modification
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Figure 25: Transrepressive bioactivity of steroid derivatives 3c and 3d
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Figure 26: Transrepressive activity of derivatives
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at R2 (Figure 27) to conclude if the ability to repress the cytokine is improved by
the single modification of 2-furoyl or does the combination of the two
derivatizations

lead

to

the

transrepressive

bioactivity.

The

2-

mercaptobenzothiazole modification did not help the steroids ability to repress
the IL-6β cytokine but it did show the ability to inhibit the dimerization of the GR
across 4 of the 5 scaffolds tested. Desonide was the only scaffold that did not
show an improved transactivating profile after the first derivatization. A derivative
of

budesonide

was

also

made

containing

the

modification

with

2-

mercaptobenzothiazole although it had not been tested yet. Budesonide and
desonide make up a subclass of acetonide glucocorticoids that contain a
heterocyclic acetal between carbon C-16 and C-17. This could be hypothesized
that the hydroxyl group at C-17 in combination with 2-mercaptobenzothiazole is
leading to the ability to inhibit the dimerization of the receptor. The two analogues
synthesized that tested the best in the 3xGRE promoter assay were 2b and 2c.
(Figure 27).
The greatly improved transactivation profiles of 2b and 2c displayed the ability to
inhibit promoter activity 4 times better at 0.1 nM than the steroid backbone. 2c
was the overall best analogue as it displayed little promoter activity over the
control at concentration up to 100 nM. Further indication that the C-17 hydroxyl
group is important to preferred transactivating properties is shown through the
second derivatization with 2-furoyl. The addition of the 2-furioyl group negatively
impacts all the steroid scaffold tested in terms of transactivating profile, although
still better than the original steroid backbone. Flumetasone, known as one of the
strongest synthetic glucocorticoids is only used in a medicinal setting due to the
side

effects

of

the

drug

heightened.

Its

derivatization

with

2-

mercatptobenzothiazole saw 5-fold improvement at 0.1nM over the steroid
backbone and less than a 5-fold promoter activity over the control across all
concentrations up to 10 μM.
Selective compounds were subjected to a screen of additional genes using
832/13 rat insulinoma cells known to be involved with β-cell identity and insulin
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Figure 27: Transactivating profiles of 2b and 2c
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secretion. The gene of interest SGK1 (serum and glucocorticoid-inducible kinase
1) displayed a 10-fold change in mRNA by dexamethasone at 6 nM, but 2a, and
3a only shoed a 2-fold increase at the same concentration. Betamethasone
derivatives subjected to screening of SGK1 showed the steroid derivatives have
a relative promoter activity 5 to 6 times lower than steroid scaffold. Prednisolone
derivatives continued to show the most promise as a future therapeutic agent as
gene studies of SGK1 shoed a relative mRNA abundance increases 2-fold for 2c,
only slightly less effective than the steroid scaffold. Although flumetasone did not
display a dissociated profile for its anti-inflammatory, its relative mRNA
abundance in SGK1 studies for the first derivatization increases 5-fold in 832/13
rat insulinoma cells, compared to 6-fold in flumetasone. Budesonide derivative 2f
did not increase relative mRNA abundance.

2.7 Conclusion
Glucocorticoids are lipophilic compounds that target the GR impacting multiple
cellular processes including in the immune system, lipid and glucose
homeostasis and reproductive function. The variety of cellular processes
manipulated by steroidal or non-steroidal GC’s makes it useful across clinical
settings. Although they are very effective to treat the underlying cause, long time
use of GC’s produce a hoard of undesired side effects. 111 This has led to the
search for new GC’s that retain its therapeutic index with less side effects. We
have developed a series of steroidal and non-steroidal GC’s that have the
desired anti-inflammatory profile and haven’t been tested before using rodent
and human islets β-cell lines. The steroidal GC’s derivatized with 2mercaptobenzothiazole, 2a, 2b, and 2c all displayed impressive transactivating
profiles.

The

molecules

that

were

synthesized

with

both

the

2-

mercaptobenzothiazole and 2-furoyl groups, 3c and 3d displayed impressive
transrepressive profiles. There is a clear distinction is the transcription ability of a
steroidal glucocorticoid upon derivatization with 2-mercaptobenzothiazole. The
addition of the heterocycle to a commercially available steroidal scaffold retained
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desirable transrepressive properties of the steroid as well as improved the
transactivation potential across all scaffolds tested. The findings in this study of
steroidal derivatization can aid future GC drug targets considering the properties
observed derivatizing C17 of the steroid backbone. The limitation of the study on
the steroidal glucocorticoids is that no current data on insulin suppression has
been acquired thus far. Commercial GC’s have the tendency to impair insulin
sensitivity in both skeletal and liver muscle, adipose tissue and impair β-cell
function, therefore additional experiments will need to address these issues. 2a,
2b, 2c, 3c and 3d are prime candidates for insulin secretion experiments as they
have displayed the more favorable anti-inflammatory profile.
The non-steroidal glucocorticoids were all subjected to testing anti-inflammatory
activity as well as the top candidates moving forward to insulin secretion testing.
The transcription properties of the compounds where tested and compared to
dexamethasone

for

transrepressive

and

transactivating

potential. When

comparing the compounds to dexamethasone for repression of IL-1β-mediated
increase in CCL2 gene expression the synthetic glucocorticoid showed minimal
improvement over dexamethasone. The transcription of the 3xGRE containing
promoter construct was compared between dexamethasone and the synthetic
non-steroidal GC’s with the results generating two molecules containing a
desirable profile. 30 of the 32 compounds were found to drive transactivation
potential of the 3xGRE comparable to dexamethasone. The two compounds that
did not express any transactivation potential were compounds 11aa and 11ab.
The dissociated transcription profile of 11aa and 11ab are desired for clinical
applications. The compounds were then subjected to insulin secretion testing
comparing the synthetic GC’s to DMSO and dexamethasone at 3- and 15-mM
concentrations. 11aa induced a 1.5-fold increase over dexamethasone in terms
of

insulin

secretion,

while

13aa

displayed

little

improvement

over

dexamethasone. Molecular modeling of the non-steroidal GC’s reveals the
beneficial interactions with the human glucocorticoid receptor that may be
applied in future endeavors with this molecular scaffold.
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The comparison of the structural-activity relationship of the GC-GR between the
synthetic steroidal and non-steroidal compounds in the study is dampened
because of the absence of insulin secretion data on steroidal compounds.
Although comparisons can be made of the structure-activity relationship of the
anti-inflammatory properties between the compounds. The addition of steric bulk
in both compounds eventually led to an unfavorable profile. For the steroidal
GC’s, the second derivatization with furoyl added caused unfavorable activity. As
for the non-steroidal GC’s the addition of any bulk caused transactivation
potential. The steric bulk likely caused disruption of the hydrogen bonding of the
C21 hydroxyl group.
In summary the glucocorticoids synthesized and purified showed potential usage
as a general anti-inflammatory drug or used as a specific compound for targeted
treatment of existing conditions. Of the 42 glucocorticoids synthesized, 5
compounds displayed the dissociated transcription profile desired increasing
CCL2 gene transcription as well as refraining from increasing 3xGRE promoter
activity. The compounds containing the desired profile we found to be 2a, 2b, 2c,
3c, 3d, 11aa and 13aa. Future work targeting the GR can benefit from some of
the structure-activity relationships that we have observed.
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2.8 Chapter II Appendix
2.8.1 Non-steroidal glucocorticoid CCL2 bioassay data
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2.8.2 Non-steroidal glucocorticoid 3xGRE bioassay data
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2.8.3 Non-steroidal glucocorticoid GSIS bioassay data
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2.8.4 Annotated characterization data of novel and previously reported nonsteroidal glucocorticoids
4-Fluorophenyl analogues
1-(4-fluorophenyl)-4a-methyl-1,4,4a,6,7,8-hexahydrospiro[benzo[f]indazole-5,2'[1,3]dioxolane] (7a): 1H-NMR (CDCl3, 499.73 MHz) δ 1.21 (s, 3H), 1.65-1.82 (m,
4H), 2.27-2.30 (d, 1H), 2.42-2.52 (m, 2H), 3.14-3.17 (d, 1H), 3.97-4.10 (m, 4H),
6.20 (s, 1H), 7.14 (m, 2H), 7.41-7.44 (m, 3H).
1-(4-fluorophenyl)-4a-methyl-1,4,4a,6,7,8-hexahydro-5H-benzo[f]indazol-5-one
(8a): 1H-NMR (CDCl3, 499.73 MHz) δ 1.25 (s, 3H), 1.63-1.72 (m, 1H), 2.06-2.12
(m, 1H), 2.51-2.57 (m, 2H), 2.60-2.69 (m, 2H), 2.87-2.91 (s, 2H), 6.29 (s, 1H),
7.15-7.18 (t, 2H), 7.44-7.47 (m, 2H), 7.48 (s, 1H).
1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazole-5carbaldehyde (10a): 1H-NMR (CDCl3, 499.73 MHz) δ 1.25 (s, 3H), 1.35-1.45 (m,
2H), 1.68-1.77 (m, 1H), 1.89-1.95 (m, 2H), 2.32-2.42 (m, 3H), 2.87-2.90 (d, 1H),
3.07-3.10 (d, 1H), 6.18 (s, 1H), 7.12-7.16 (t, 2H), 7.41-7.44 (m, 3H), 9.93 (s, 1H).
1-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5yl)ethan-1-ol (11aa): 1H-NMR (CDCl3, 499.73 MHz) δ 1.14 (s, 3H), 1.26-1.28 (d,
3H), 1.41-.147 (dd, 2H), 1.63-1.68 (dd, 1H), 1.73-1.80 (m, 1H), 1.90-1.97 (m,
1H), 2.31-2.43 (m, 2H), 2.46-2.52 (d, 1H), 2.98-3.03 (d, 1H), 4.25 (s, 1H), 6.10 (s,
1H), 7.11-7.19 (m, 2H), 7.41-7.47 (m, 3H).
2-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5yl)propan-2-ol (13aa): 1H-NMR (CDCl3, 300.08 MHz) δ 1.14 (s, 3H), 1.26-1.28 (d,
3H), 1.35-1.47 (m, 2H), 1.58 (s, 3H), 1.63-1.68 (dd, 1H), 1.73-1.80 (m, 1H), 1.891.98 (m, 1H), 2.26-2.42 (m, 2H), 2.46-2.52 (d, 1H), 2.98-3.03 (d, 1H), 6.10 (s,
1H), 7.12-7.18 (m, 2H), 7.41-7.47 (m, 3H).
(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5yl)(phenyl)methanol (11ab): 1H-NMR (CDCl3, 499.73 MHz) δ 1.18 (s, 3H), 1.521.58 (m, 2H), 1.60-1.63 (dd, 1H), 1.70-1.74 (m, 2H), 2.17-2.21 (m, 1H), 2.28-2.36
(m, 1H), 2.66-2.69 (d, 1H), 3.08-3.11 (d, 1H), 5.10 (d, 1H), 6.02 (s, 1H), 7.04-7.08
(m, 2H), 7.16-7.18 (m, 1H), 7.27-7.29 (m, 4H), 7.35-7.38 (m, 3H).
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1-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)1-phenylethan-1-ol (13ab): 1H-NMR (CDCl3, 499.73 MHz) δ 1.27 (s, 3H), 1.561.65 (m, 2H), 1.67 (s, 3H), 1.74-1.80 (m, 1H), 2.02-2.08 (dd, 1H), 2.23-2.44 (m,
2H), 2.58-2.64 (d, 1H), 3.12-3.17 (d, 1H), 6.09 (s, 1H), 7.10-7.16 (t, 2H), 7.277.52 (m, 8H).
(4-fluorophenyl)(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1Hbenzo[f]indazol-5-yl)methanol (11ac): 1H-NMR (CDCl3, 300.08 MHz) δ1.26 (s,
3H), 1.65-1.69 (m, 3H), 1.77-1.86 (m, 1H), 2.26-2.41 (m, 2H), 2.72-2.77 (d, 1H),
3.17-3.22 (d, 1H), 5.19-5.22 (s, 1H), 6.12 (s, 1H), 7.02-7.08 (t, 2H), 7.13-7.19 (t,
2H), 7.30-7.34 (dd, 2H), 7.44-7.48 (m, 3H).
1-(4-fluorophenyl)-1-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1Hbenzo[f]indazol-5-yl)ethan-1-ol (13ac): 1H-NMR (CDCl3, 499.73 MHz) δ 1.25 (s,
3H), 1.51-1.62 (m, 2H), 1.66 (s, 3H), 1.72-1.81 (m, 2H), 1.95-2.05 (m, 1H), 2.212.40 (m, 2H), 2.58-2.64 (d, 1H), 3.14-3.20 (d, 1H), 6.09 (s, 1H), 7.00-7.06 (t, 2H),
7.11-7.17 (t, 2H), 7.25-7.28 (m, 1H), 7.41-7.49 (m, 4H).
(3,4-difluoro-5-methoxyphenyl)(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8hexahydro-1H-benzo[f]indazol-5-yl)methanol (11ad):

1

H-NMR (CDCl3, 300.08

MHz) δ 1.26 (s, 3H), 1.54-1.57 (m, 1H), 1.64-1.72 (m, 1H), 1.82-1.86 (m, 2H),
2,28-2.46 (m, 3H), 2.72-2.77 (d, 1H), 3.17-3.22 (d, 1H), 3.92 (s, 3H), 5.12 (s, 1H),
6.12 (s, 1H), 6.72-6.80 (m, 2H), 7.15-7.21 (m, 2H), 7.45-7.54 (m, 3H).
1-(3,4-difluoro-5-methoxyphenyl)-1-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8hexahydro-1H-benzo[f]indazol-5-yl)ethan-1-ol (13ad):

1

H-NMR (CDCl3, 499.73

MHz) δ 1.26 (s, 3H), 1.54-1.60 (m, 2H), 1.62 (s, 3H), 1.64-1.66 (m, 1H), 1.801.85 (m, 1H), 1.96-1.99 (dd, 1H), 2.24-2.30 (m, 1H), 2.34-2.42 (m, 1H), 2.57-2.60
(d, 1H), 3.07-3.11 (d, 1H), 3.91 (s, 3H), 6.10 (s, 1H), 6.87-6.91 (m, 2H), 7.12-7.16
(t, 2H), 7.28 (s, 1H), 7.42-7.45 (m, 2H).
(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5yl)(thiophen-3-yl)methanol (11ae): 1H-NMR (CDCl3, 499.73 MHz) δ 1.24 (s, 3H),
1.65-1.93 (m, 5H), 2.27-2.48 (m, 2H), 2.67-2.72 (d, 1H), 3.08-3.15 (d, 1H), 5.24
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(s, 1H), 6.12 (s, 1H), 6.94-6.99 (m, 1H), 7.12-7.24 (m, 3H), 7.30-7.33 (m, 1H),
7.43-7.48 (m, 3H).
1-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)1-(thiophen-3-yl)ethan-1-ol (13ae): 1H-NMR (CDCl3, 499.73 MHz) δ 1.27 (s, 3H),
1.52-1.62 (m, 3H), 1.68 (s, 3H), 2.01-2.06 (m, 1H), 2.24-2.43 (m, 3H), 2.64-2.69
(d, 1H), 3.24-3.30 (d, 1H), 6.10 (s, 1H), 7.14-7.17 (m, 3H), 7.27-7.30 (m, 1H),
7.33 (s, 1H), 7.42-7.47 (m, 3H).
3-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)3-hydroxypropanenitrile (11af): white solid obtained in 46% yield; mp 121-123.8
˚C; TLC (Silica G w/UV254) 25% EtOAc in hexanes, Rf = 0.14; [α]D20 = +60 (c
1.0, MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ 1.04-1.13 (s, 3H), 1.25-1.46 (m,
2H), 1.61-1.71 (m, 2H), 1.78-1.97 (m, 2H), 2.30-2.42 (m, 2H), 2.47-2.72 (m, 3H),
2.93-3.21 (d, 1H), 4.16-4.40 (m, 1H), 6.12 (s, 1H), 7.14-7.44 (m, 5H);

13

C-NMR

(CDCl3, 125.66 MHz) δ 19.32, 20.91, 25.37, 26.20, 32.98, 33.19, 34.64, 52.82,
66.62, 109.76, 115.96, 116.14, 125.32, 137.86; IR (NaCl, thin film) νmax (cm-1):
3335 (OH), 3030 (w), 2934, 2867, 2249 (CN), 1619, 1518, 1225, 840; HRMS
(DART-RTOF) m/z: [M+H]+ Calcd for C21H23FN3O, 352.18197; found 352.18293.
3-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)3-hydroxybutanenitrile (12af): white solid obtained in 16% yield; mp 120-129 ˚C;
TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 0.11; [α]D20 = +60 (c 1.0,
CHCl3); 1H-NMR (CDCl3, 499.73 MHz) δ 1.20 (s, 3H), 1.45-1.49 (m, 2H), 1.821.87 (t, 2H), 1.93-1.97 (d, 1H), 2.32-2.44 (m, 3H), 2.74-2.77 (d, 1H), 2.82-2.88
(m, 2H), 3.53-3.61 (s, 2H), 6.15 (s, 1H), 7.14-7.44 (m, 5H);

13

C-NMR (CDCl3,

125.66 MHz) δ 18.53, 25.21, 25.61, 31.72, 33.85, 34.75, 41.16, 59.60, 110.18,
112.91, 113.49, 116.00, 135.61, 136.29, 137.72, 146.60, 160.56, 162.53, 199.38;
IR (NaCl, thin film) νmax (cm-1) 2955, 2920, 2850, 1723 (m), 1514 (m), 1462,
1377, 1222; HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C21H21FN3O,
350.16632; found 350.16529.
1-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)2,2-dimethylpropan-1-ol (11ag): 1H-NMR (CDCl3, 499.73 MHz) δ 0.97 (s, 9H),
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1.08 (s, 3H), 1.38-1.45 (m, 1H), 1.59-1.67 (m, 1H) 1.72-1.79 (m, 2H), 1.83-1.87
(m, 1H), 2.30-2.35 (m, 1H), 2.36-2.44 (m, 1H), 2.45-2.48 (d, 1H), 2.82-2.85 (d,
1H), 3.50 (s, 1H), 6.13 (s, 1H), 7.13-7.17 (t, 2H), 7.41 (s, 1H), 7.43-7.47 (m, 2H).
2-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)3,3-dimethylbutan-2-ol (12ag): beige solid obtained in 14% yield; mp 98 - 101˚C;
TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 0.54; [α]D20 = +8.7 (c 1.0,
MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ 1.19 (s, 9H), 1.33 (s, 3H), 1.40-1.50 (m,
1H), 1.55 (s, 1H), 1.70-1.74 (dd, 1H), 2.27-2.33 (m, 1H), 2.42-2.53 (m, 1H), 2.562.68 (m, 2H), 3.08-3.13 (m, 1H), 6.11 (s, 1H), 7.12-7.18 (t, 2H), 7.36 (s, 1H),
7.42-7.46 (dd, 2H);

13

C-NMR (CDCl3, 125.66 MHz) δ 19.22, 26.03, 27.02, 27.50,

31.99, 34.63, 41.82, 45.42, 53.04, 109.06, 113.60, 115.92, 119.70, 125.32,
135.81, 136.61, 137.77, 149.32, 160.46, 162.43, 218.05; IR (NaCl, thin film) νmax
(cm-1) 2927, 2855, 1699, 1516, 1479, 1464, 1375, 1366, 1292, 1224, 1176, 1152,
1134, 1000; HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C23H28FN2O, 367.2180;
found 367.2179.
4-methylphenyl analogues
4a-methyl-1-(p-tolyl)-1,4,4a,6,7,8-hexahydrospiro[benzo[f]indazole-5,2'[1,3]dioxolane] (7b): 1H-NMR (CDCl3, 300.08 MHz) δ 1.14 (s, 3H), 1.56-1.79 (m,
5H), 2.19-2.22 (m, 1H), 2.32 (s, 3H), 2.42-2.45 (d, 1H), 3.08-3.11 (d, 1H), 3.924.01 (m, 4H), 6.18 (s, 1H), 7.17-7.19 (m, 2H), 7.27-7.29 (m, 2H), 7.33 (s, 1H).
4a-methyl-1-(p-tolyl)-1,4,4a,6,7,8-hexahydro-5H-benzo[f]indazol-5-one (8b):

1

H-

NMR (CDCl3, 300.08 MHz) δ 1.24 (s, 3H), 1.59-1.79 (m, 2H), 2.03-2.13 (m, 1H),
2.40 (s, 3H), 2.49-2.70 (m, 3H), 2.90 (s, 2H), 6.32 (s, 1H), 7.26-7.28 (m, 2H),
7.35-7.38 (m, 2H), 7.47 (s, 1H).
4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazole-5carbaldehyde (10b): 1H-NMR (CDCl3, 300.08 MHz) δ 1.12 (s, 3H), 1.33-1.50 (m,
1H), 1.67-1.76 (m, 1H), 1.81-1.98 (m, 2H), 2.34-2.46 (m, 6H), 2.88-2.94 (d, 1H),
3.08-3.13 (d, 1H), 6.21 (s, 1H), 7.25-7.28 (m, 2H), 7.34-7.37 (m, 2H), 7.43 (s,
1H), 9.91 (s, 1H).
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1-(4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)ethan-1ol (11ba): white solid obtained in 50% yield; mp 178.1-181.0 ˚C; TLC (Silica G
w/UV254) 30% EtOAc in hexanes, Rf = 0.16; [α]D20 = -16 (c 1.0, MeOH); 1H-NMR
(CDCl3, 499.73 MHz) δ 1.13 (s, 3H), 1.23-1.29 (m, 3H), 1.34-1.45 (m, 2H), 1.561.62 (m, 2H), 1.72-1.78 (m, 1H), 1.90-1.94 (m, 1H), 2.27-2.30 (m, 1H), 2.32-2.37
(m, 4H) 2.47-2.50 (d, 1H), 2.97-3.00 (d, 1H), 6.14 (s, 1H), 7.23-7.26 (d, 2H),
7.34-7.36 (d, 2H), 7.40 (s, 1H);

13

C-NMR (CDCl3, 125.66 MHz) δ 19.21, 20.81,

24.34, 25.85, 33.32, 34.67, 41.14, 54.89, 56.00, 66.11, 109.50, 113.47, 123.47,
129.65, 136.81, 137.28, 137.60, 149.57; IR (NaCl, thin film) νmax (cm-1): 3315
(OH), 3043 (w), 2962, 2936, 2862, 1620, 1518 (w), 1425, 1132, 820; HRMS
(DART-RTOF) m/z: [M+H]+ Calcd for C21H27N2O, 323.21179; found 323.21001.
2-((4aR)-4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5yl)propan-2-ol (13ba): white solid obtained in 55% yield; mp 173-176 ˚C; TLC
(Silica G w/UV254) 25% EtOAc in hexanes, Rf = 0.17; [α]D20 = -75 (c 1.0, MeOH);
1

H-NMR (CDCl3, 499.73 MHz) δ 1.19 (s, 3H), 1.33-1.37 (s, 8H), 1.38-1.39 (d,

1H), 1.66-1.69 (d, 1H), 1.77-1.80 (dt, 1H), 1.84-1.87 (dt, 1H), 2.31 (m, 1H), 2.39
(s, 3H), 2.73-2.76 (d, 1H), 3.53-3.57 (d, 1H), 6.16 (s, 1H) 7.24-7.25 (d, 2H), 7.357.38 (d, 2H), 7.40 (s, 1H);

13

C-NMR (CDCl3, 125.66 MHz) δ 19.65, 26.38, 27.48,

29.70, 33.91, 34.52, 36.19, 43.57, 57.61, 75.52, 109.76, 115.22, 123.26, 129.63,
136.59, 137.38, 150.95; IR (NaCl, thin film) νmax (cm-1): 3395 (OH), 2928, 2855,
1611 (w), 1519 (m); HRMS (ESI-RTOF) m/z: [M+H]+ Calcd for C22H29N2O,
337.2274; found 337.2200.
(4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5yl)(phenyl)methanol (11bb): white solid obtained in 28% yield; mp 184-187 ˚C;
TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 0.20; [α]D20 = -12 (c 1.0,
MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ 1.26 (s, 3H), 1.60-1.81 (m, 5H), 2.232.28 (d, 1H), 2.36-2.43 (m, 4H), 2.74-2.77 (d, 1H) 3.15-3.18 (d, 1H), 5.17 (s, 1H),
6.15 (s, 1H), 7.23-7.27 (d, 3H), 7.34-7.38 (m, 6H), 7.41 (s, 1H);

13

C-NMR (CDCl3,

125.66 MHz) δ 19.90, 21.05, 25.79, 41.28, 56.66, 71.95, 109.51, 113.67, 123.52,
125.38, 126.78, 128.16, 129.68, 137.60, 145.70, 149.77; IR (NaCl, thin film) νmax
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(cm-1): 3319 (OH), 3039 (w), 2929, 2868, 1610 (w), 1519 (m), 821; HRMS
(DART-RTOF) m/z: [M+H]+ Calcd for C26H29N2O, 385.22744; found 385.22612.
1-((4aR)-4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)-1phenylethan-1-ol (13bb): white solid obtained in 82% yield; mp 172-174.5 ˚C;
TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 0.27; [α]D20 = -26 (c 1.0,
MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ 1.27 (s, 3H), 1.62-1.66 (m, 2H), 1.68 (s,
3H), 1.74-1.79 (m, 2H), 2.04-2.07 (d, 1H), 2.24-2.28 (d, 1H), 2.33-2.40 (m, 4H),
2.60-2.63 (d, 1H), 3.10-3.13 (d, 1H), 6.14 (s, 1H), 7.23-7.29 (m, 4H), 7.33-7.36
(m, 4H), 7.49-7.52 (m, 2H);

13

C-NMR (CDCl3, 125.66 MHz) δ 20.41, 21.02,

25.82, 26.11, 28.40, 29.68, 34.20, 35.90, 44.00, 56.78, 78.79, 109.52, 115.37,
123.26, 125.56, 126.74, 128.02, 129.62, 136.05, 136.53, 137.41, 137.72, 151.03;
IR (NaCl, thin film) νmax (cm-1): 3365 (OH), 3054 (w), 2928, 2858, 1610 (w), 1519
(m), 821; HRMS (ESI-RTOF) m/z: [M+H]+ Calcd for C27H31N2O, 399.2430; found
399.2368.
(4-fluorophenyl)(4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol5-yl)methanol (11bc): white solid obtained in 11.5% yield; mp 188-191 ˚C; TLC
(Silica G w/UV254) 25% EtOAc in hexanes, Rf = 0.24; [α]D20 = -24 (c 1.0, MeOH);
1

H-NMR (CDCl3, 499.73 MHz) δ 1.26 (s, 3H), 1.50-1.61 (m, 3H), 1.67-1.71 (m,

2H), 1.79-1.82 (d, 1H), 2.25-2.28 (d, 1H), 2.39 (s, 3H), 2.74-2.77 (d, 1H), 3.163.20 (d, 1H), 5.19 (s, 1H), 6.16 (s, 1H), 7.02-7.46 (m, 9);

13

C-NMR (CDCl3,

125.66 MHz) δ19.19, 21.04, 25.74. 33.25, 35.24, 41.24, 56.75, 71.47, 109.62,
113.54, 114.58, 123.50, 126.92, 129.69, 136.68, 136.90, 137.23, 137.58, 141.26,
149.48, 160.71, 162.66; IR (NaCl, thin film) νmax (cm-1): 3312 (OH), 3041 (w),
2931, 2867, 2830, 1898, 1603, 1518, 1219, 819; HRMS (DART-RTOF) m/z:
[M+H]+ Calcd for C26H28FN2O, 403.21802; found 403.21649.
1-(4-fluorophenyl)-1-((4aR)-4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1Hbenzo[f]indazol-5-yl)ethan-1-ol (13bc): white solid obtained in 80% yield; mp
188.5-191 ˚C; TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 0.25; [α]D20 =
-9 (c 1.0, MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ 1.26 (s, 3H), 1.60-1.63 (m,
3H), 1.66 (s, 3H), 1.75-1.79 (d, 1H), 1.99-2.02 (d, 1H), 2.24-2.27 (d, 1H), 2.39 (s,
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3H), 2.60-2.63 (d, 1H), 3.12-3.15 (d, 1H), 5.30 (s, 1H), 6.14 (s, 1H), 7.01-7.48 (m,
9H);

13

C-NMR (CDCl3, 125.66 MHz) δ 20.40, 21.02, 25.83, 26.16, 28.41, 34.15,

36.03, 43.98, 56.89, 78.55, 109.60, 114.59, 115.25, 123.26, 127.24, 129.63,
136.58, 137.69, 150.94; IR (NaCl, thin film) νmax (cm-1): 3315 (OH), 3020 (w),
2928, 2860, 1600, 1519, 1222; HRMS (DART-RTOF) m/z: [M+H]+ Calcd for
C27H30FN2O, 417.23367; found 417.23232.
(3,4-difluoro-5-methoxyphenyl)(4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1Hbenzo[f]indazol-5-yl)methanol (11bd): white solid obtained in 76% yield; mp 97101 ˚C; TLC (Silica G w/UV254) 25% EtOAc in hexanes, Rf = 0.22; [α]D20 = +31
(c 1.0, MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ 1.25 (m, 3H), 1.37-1.50 (m, 2H),
1.54-1.65 (m, 2H), 1.76-1.79 (d, 1H), 2.04 (s, 3H), 2.26-2.29 (d, 1H), 2.72-2.75
(d, 1H), 3.14-3.17 (d, 1H), 3.88 (s, 3H), 5.10 (s, 1H), 6.16 (s, 1H), 6.72-6.78 (m,
2H), 7.24-7.46 (m, 6H);

13

C-NMR (CDCl3, 125.66 MHz) δ 14.18, 19.94, 21.04,

25.70, 33.17, 35.31, 41.20, 56.71, 60.38, 71.28, 105.52, 106.04, 109.70, 113.35,
123.36, 129.66, 136.67, 136.99, 137.17, 137.55, 149.25; IR (NaCl, thin film) νmax
(cm-1): 3387 (OH), 3050 (w), 2927, 2850, 1623, 1522, 1454, 1426, 1339, 1226,
1097; HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C27H29F2N2O2, 451.21916;
found 451.21790.
1-(3,4-difluoro-5-methoxyphenyl)-1-((4aR)-4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8hexahydro-1H-benzo[f]indazol-5-yl)ethan-1-ol (13bd): white solid obtained in
94% yield, mp 181-183 ˚C; TLC (Silica G w/UV254) 30% EtOAc in hexanes, R f =
0.19; [α]D20 = +13 (c 3.0, MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ 1.22-1.35 (m,
6H), 1.58-1.62 (m, 4H), 1.79-1.83 (d, 1H), 1.96-1.99 (d, 1H), 2.25-2.28 (d, 1H),
2.34-2.44 (s, 3H), 2.57-2.61 (d, 1H), 3.05-3.08 (d, 1H), 3.91-3.96 (s, 3H), 6.15 (s,
1H), 6.87-6.92 (m, 2H), 7.23-7.30 (m, 4H), 7.36 (s, 1H); 13C-NMR (CDCl3, 125.66
MHz) δ 20.53, 25.64, 26.24, 28.90, 33.96, 35.77, 44.02, 56.34, 123.27, 129.65,
136.66; IR (NaCl, thin film) νmax (cm-1): 3348 (OH), 2927, 2853, 1622, 1520,
1451, 1420, 1334, 1228, 1101; HRMS (ESI-RTOF) m/z: [M+H]+ Calcd for
C28H31F2N2O2, 465.2348; found 465.2283.
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(4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)(thiophen2-yl)methanol (11be): white solid obtained in 36% yield; mp 109-114 ˚C; TLC
(Silica G w/UV254) 25% EtOAc in hexanes, Rf = 0.26; [α]D20 = -17 (c 1.0, MeOH);
1

H-NMR (CDCl3, 499.73 MHz) δ 1.23 (s, 3H), 1.62-1.91 (m, 6H), 2.26-2.31 (m,

1H), 2.40 (s, 3H), 2.67-2.72 (m, 1H), 3.06-3.14 (m, 1H), 5.39 (s, 1H), 6.16 (s,
1H), 6.95-7.43 (m, 8H);

13

C-NMR (CDCl3, 125.66 MHz) δ 19.07, 21.03, 21.64,

23.60, 24.35, 25.83, 33.32, 33.51, 34.67, 35.08, 40.64, 41.13, 54.89, 56.02,
66.12, 67.89, 109.57, 114.13, 123.42, 129.65, 136.46, 137.59, 149.61; IR (NaCl,
thin film) νmax (cm-1): 3319 (OH), 3106 (w), 3045 (w), 2928, 2856, 2836, 1611,
1540 (m); HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C24H27N2OS, 391.18386;
found 391.13976.
1-((4aR)-4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)-1(thiophen-2-yl)ethan-1-ol (13be): white solid obtained in 76% yield; mp 90-95 ˚C;
TLC (Silica G w/UV254) 25% EtOAc in hexanes, Rf = 0.28; [α]D20 = -12 (c 3.0,
MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ 1.25 (s, 3H), 1.40-1.41 (d, 1H), 1.571.59 (d, 1H), 1.65 (s, 3H), 1.69-1.70 (d, 2H), 1.76-1.78 (d, 1H), 2.03-2.06 (d, 1H),
2.26-2.28 (d, 1H), 2.39 (s, 3H), 2.66-2.69 (d, 1H), 3.22-3.25 (d, 1H), 6.15 (s, 1H),
7.12-7.37 (m, 8H);

13

C-NMR (CDCl3, 125.66 MHz) δ 20.13, 21.02, 26.16, 28.19,

29.68, 34.31, 35.80, 43.88, 56.70, 109.66, 115.39, 119.69, 123.26, 125.64,
126.49, 129.63, 136.56, 137.73, 150.91; IR (NaCl, thin film) νmax (cm-1): 3381
(OH), 3105 (w), 3042 (w), 2928, 2859, 1611, 1518 (m), 821; HRMS (DARTRTOF) m/z: [M+H]+ Calcd for C25H29N2OS, 405.1995; found 405.1997.
4-methoxyphenyl analogues
1-(4-methoxyphenyl)-4a-methyl-1,4,4a,6,7,8-hexahydrospiro[benzo[f]indazole5,2'-[1,3]dioxolane] (7c): 1H-NMR (CDCl3, 300.08 MHz) δ 1.21 (s, 3H), 1.64 (m,
2H), 1.84 (m, 2H), 2.24-2.30 (m, 1H), 2.38-2.45 (m, 1H), 2.48-2.53 (d, 1H), 3.133.19 (d, 1H), 3.86 (s, 3H), 3.99-4.08 (m, 4H), 6.20 (s, 1H), 6.95-6.98 (m, 2H),
7.36-7.39 (m, 3H).
1-(4-methoxyphenyl)-4a-methyl-1,4,4a,6,7,8-hexahydro-5H-benzo[f]indazol-5one (8c): 1H-NMR (CDCl3, 300.08 MHz) δ 1.24 (s, 3H), 1.59-1.79 (m, 2H), 2.03153

2.13 (m, 1H), 2.40 (s, 3H), 2.49-2.70 (m, 3H), 2.90 (s, 2H), 6.32 (s, 1H), 7.267.28 (m, 2H), 7.35-7.38 (m, 2H), 7.47 (s, 1H).
1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazole-5carbaldehyde (10c): 1H-NMR (CDCl3, 300.08 MHz) δ 1.11 (s, 3H), 1.33-1.48 (m,
1H), 1.65-1.80 (m, 1H), 1.88-1.96 (m, 2H), 2.32-2.45 (m, 3H), 2.85-2.92 (d, 1H),
3.06-3.11 (d, 1H), 3.84 (s, 3H), 6.16 (s, 1H), 6.96-6.99 (m, 2H), 7.36-7.40 (m,
3H), 9.89 (s, 1H).
1-(1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5yl)ethan-1-ol (11ca): white solid obtained in 58% yield; mp 156-159 ˚C; TLC
(Silica G w/UV254) 25% EtOAc in hexanes, Rf = 0.11; [α]D20 = +25 (c 1.0,
MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ 1.13 (s, 3H), 1.23-1.29 (m, 4H), 1.341.45 (m, 3H), 1.74-1.78 (d, 1H),1.88-1.95 (d, 1H), 2.28-2.31 (d, 1H), 2.35-2.39
(m, 1H), 2.47-2.51 (d, 1H), 2.98-3.01 (d, 1H), 3.84-3.87 (s, 3H), 6.10 (s, 1H),
6.96-7.40 (m, 5H);

13

C-NMR (CDCl3, 125.66 MHz) δ 19.21, 20.80, 24.36, 25.85,

33.31, 34.68, 41.16, 54.89, 55.49, 66.10, 109.38, 113.42, 114.25, 133.01,
136.73, 137.32,149.51, 158.54; IR (NaCl, thin film) νmax (cm-1): 3376 (OH), 3020
(w), 2962, 2931, 2862, 1612, 1517, 1250, 831; HRMS (DART-RTOF) m/z:
[M+H]+ Calcd for C21H27N2O2, 339.20670; found 339.20344.
2-((4aR)-1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1Hbenzo[f]indazol-5-yl)propan-2-ol (13ca): white solid obtained in 58% yield; mp
194-197 ˚C; TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 0.08; [α]D20 = 17 (c 1.0, MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ 1.19 (s, 3H) 1.30-1.38 (d,
6H), 1.48-1.55 (m, 1H), 1.66-1.69 (d, 1H), 1.76-1.87 (dd, 2H), 2.27-2.37 (m, 3H),
2.73-2.76 (d, 1H), 3.53-3.57 (d, 1H), 3.85 (s, 3H), 6.11 (s, 1H) 6.95-7.41 (m, 5H);
13

C-NMR (CDCl3, 125.66 MHz) δ 19.66, 26.38, 27.48, 28.39, 29.68, 33.91, 34.51,

36.20, 43.60, 55.52, 57.61, 75.49, 109.57, 114.24, 114.96, 124.86, 133.10,
136.29, 137.41, 150.90, 158.42; IR (NaCl, thin film) νmax (cm-1): 3349 (OH), 3018,
2928, 2857, 1612, 1517, 1248, 831; HRMS (ESI-RTOF) m/z: [M+H]+ Calcd for
C22H29N2O2, 353.2223; found 353.2184.
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(1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5yl)(phenyl)methanol (11cb): beige solid obtained in 73% yield; mp 109.3-111.5
˚C; TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 0.11; [α]D20 = -10 (c 1.0,
MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ 1.27 (s, 3H), 1.56-1.81 (m, 6H), 2.242.27 (d, 1H), 2.36-2.44 (m, 1H), 2.75-2.78 (d, 1H), 3.17-3.20 (d, 1H), 3.85 (s, 3H),
5.20 (s, 1H), 6.11 (s, 1H), 6.96-7.44 (m, 9H);

13

C-NMR (CDCl3, 125.66 MHz) δ

19.90, 25.78, 33.28, 35.23, 41.30, 56.65, 72.02, 114.27, 125.09, 125.36, 126.84,
128.20, 132.99, 145.61, 149.62, 158.58; IR (NaCl, thin film) νmax (cm-1): 3307
(OH), 3056 (w), 2932, 2868, 2835, 1611, 1518, 1250, 833; HRMS (DART-RTOF)
m/z: [M+H]+ Calcd for C26H29N2O2, 401.22235; found 401.21952.
1-((4aR)-1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1Hbenzo[f]indazol-5-yl)-1-phenylethan-1-ol (13cb): beige solid obtained in 100%
yield, mp 105.1-108 ˚C; TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf =
0.20; [α]D20 = -30 (c 1.0, CHCl3); 1H-NMR (CDCl3, 499.73 MHz) δ 1.27 (s, 3H),
1.55-1.63 (m, 3H), 1.68 (s, 3H), 1.75-1.77 (m, 1H), 2.04-2.07 (m, 1H), 2.23-2.26
(m, 1H), 2.33-2.38 (m, 1H), 2.60-2.63 (d, 1H), 3.10-3.13 (d, 1H), 3.84 (s, 3H),
6.08 (s, 1H), 6.95-7.51 (m, 10H);

13

C-NMR (CDCl3, 125.66 MHz) δ 20.43, 25.82,

26.20, 28.38, 29.68, 34.19, 35.91, 44.03, 55.48, 56.79, 78.80, 109.33, 114.22,
115.10, 125.55, 128.01, 133.11, 136.12, 137.46, 151.03, 158.39; IR (NaCl, thin
film) νmax (cm-1): 3338 (OH), 3020 (w), 2925, 2854, 1611, 1517, 1250, 833;
HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C27H31N2O2, 415.23800; found
415.23680.
(4-fluorophenyl)(1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1Hbenzo[f]indazol-5-yl)methanol (11cc): white solid obtained in 69% yield; mp 178182 ˚C; TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 0.26; [α]D20 = +4 (c
4.0, MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ 1.26 (s, 3H), 1.56-1.58 (m, 2H),
1.66-1.70 (m, 2H), 1.79-1.82 (m, 1H), 2.25-2.28 (m, 1H), 2.37-2.40 (m, 1H), 2.732.76 (d, 1H), 3.17-3.20 (d, 1H), 3.85 (s, 3H), 5.20 (d, 1H), 6.11 (s, 1H), 6.96-7.06
(m, 4H), 7.30-7.44 (m, 5H);

13

C-NMR (CDCl3, 125.66 MHz) δ 19.84, 20.59,

21.04, 25.80, 29.68, 33.28, 35.05, 41.22, 55.69, 69.85, 109.63, 113.56, 119.81,
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123.50, 125.51, 126.00, 129.68, 137.60, 147.31, 149.4; IR (NaCl, thin film) νmax
(cm-1): 3399 (OH), 2930, 2850, 1602, 1512, 1223, 824; HRMS (DART-RTOF)
m/z: [M+H]+ Calcd for C26H28FN2O2, 419.21293; found 419.20660.
1-(4-fluorophenyl)-1-((4aR)-1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8hexahydro-1H-benzo[f]indazol-5-yl)ethan-1-ol (13cc): white solid obtained in 49%
yield; mp 182.1-185 ˚C; TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf =
0.28; [α]D20 = -51 (c 1.0, MeOH); 1H-NMR (CDCl3, 300.08 MHz) δ 1.25 (s, 3H),
1.53-1.62 (m, 2H), 1.67 (s, 3H), 1.73-1.78 (m, 1H), 1.99-2.02 (d, 1H), 2.24-2.36
(m, 3H), 2.60-2.63 (d, 1H), 3.12-3.15 (d, 1H), 3.85 (s, 3H), 6.09 (s, 1H), 6.95-7.49
(m, 9H);

13

C-NMR (CDCl3, 499.73 MHz) δ 20.42, 25.82, 26.18, 28.46, 29.69,

34.14, 36.05, 44.02, 55.53, 56.90, 78.55, 109.48, 114.23, 114.59, 114.76,
124.84, 127.24, 136.09, 137.48, 151.60; IR (NaCl, thin film) νmax (cm-1): 3363
(OH), 2929, 2840, 1600, 1517, 1250, 834; HRMS (DART-RTOF) m/z: [M+H]+
Calcd for C27H30FN2O2, 433.22858; found 433.22897.
(3,4-difluoro-5-methoxyphenyl)(1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8hexahydro-1H-benzo[f]indazol-5-yl)methanol (11cd): white solid obtained in 71%
yield, mp 174.1-177.4 ˚C; TLC (Silica G w/UV254) 30% EtOAc in hexanes, R f =
0.16; [α]D20 = -50 (c 1.0, MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ 1.26 (s, 3H),
1.52-1.56 (m, 2H), 1.66-1.69 (m, 2H), 1.80-1.84 (m, 2H), 2.26-2.29 (m, 1H), 2.732.76 (d, 1H), 3.15-3.18 (d, 1H), 3.85 (s, 3H), 3.91 (s, 3H), 5.12 (s, 1H), 6.11 (s,
1H), 6.72-6.79 (m, 2H), 6.96-6.99 (m, 2H), 7.37-7.44 (m, 3H);

13

C-NMR (CDCl3,

125.66 MHz) δ 20.00, 25.70, 33.15, 35.35, 41.23, 55.54, 56.72, 71.34, 106.04,
109.62, 113.09, 114.29, 125.09, 136.72, 137.36, 149.14, 158.65; IR (NaCl, thin
film) νmax (cm-1): 3400 (OH), 2930, 2868, 1611, 1517, 1250, 833; HRMS (DARTRTOF) m/z: [M+H]+ Calcd for C27H29F2N2O3, 467.21408; found 467.21488.
1-(3,4-difluoro-5-methoxyphenyl)-1-((4aR)-1-(4-methoxyphenyl)-4a-methyl4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)ethan-1-ol (13cd): white solid
obtained in 65% yield, mp 184-187 ˚C, TLC (Silica G w/UV254) 30% EtOAc in
hexanes, Rf = 0.13; [α]D20 = +55 (c 1.0, MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ
1.26 (s, 3H), 1.60-1.67 (m, 6H) 1.79-1.82(d, 1H), 1.96-1.99 (d, 1H), 2.24-2.39 (m,
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2H), 2.57-2.60 (d, 1H), 3.05-3.08 (d, 1H), 3.85 (s, 3H), 3.91 (s, 3H), 6.10 (s, 1H),
6.87-7.01 (m, 4H), 7.32-7.45 (m, 3H);

13

C-NMR (CDCl3, 125.66 MHz) δ 20.54,

25.65, 26.24, 28.89, 33.95, 35.79, 44.05, 55.53, 56.35, 56.78, 106.27, 106.78,
109.50, 114.25, 114.75, 124.85, 133.03, 137.42, 150.81; IR (NaCl, thin film) νmax
(cm-1): 3329 (OH), 2932, 2850, 1622, 1518, 1251, 1100, 834; HRMS (DARTRTOF) m/z: [M+H]+ Calcd for C27H30FN2O2, 433.22858; found 433.22897.
(1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5yl)(thiophen-2-yl)methanol (11ce): white solid obtained in 79% yield; mp 171173.6 ˚C; TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 0.17; [α]D20 = -6.2
(c 1.0, MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ 1.26 (m, 4H), 1.62-1.72 (m, 2H),
1.77-1.85 (m, 2H), 2.27-2.41 (m, 2H), 2.69-2.72 (d, 1H), 3.12-3.15 (d, 1H), 3.85
(s, 3H), 5.25 (s, 1H), 6.12 (s, 1H), 6.96-7.40 (m, 8H);

13

C-NMR (CDCl3, 125.66

MHz) δ 19.87, 20.59, 25.80, 33.28, 35.04, 41.26, 55.54, 55.69, 69.83, 109.44,
113.31, 114.29, 119.82, 125.11, 125.51, 126.00, 137.26, 147.31, 158.65; IR
(NaCl, thin film) νmax (cm-1): 3310 (OH), 3090 (w), 2920, 2860, 1610 (w), 1519,
1230, 830; HRMS (ESI-RTOF) m/z: [M+H]+ Calcd for C24H27N2O2S, 407.1787;
found 407.1720.
1-((4aR)-1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1Hbenzo[f]indazol-5-yl)-1-(thiophen-2-yl)ethan-1-ol (13ce): white solid obtained in
48% yield; mp 146-148.5 ˚C; TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf
= 0.16; [α]D20 = +12 (c 1.0, MeOH); 1H-NMR (CDCl3, 499.73 MHz) δ1.25 (s, 3H),
1.59-1.65 (m, 2H), 1.68 (s, 3H), 1.73-1.78 (m, 2H), 2.03-2.06 (d, 1H), 2.25-2.36
(m, 2H), 2.65-2.69 (d, 1H), 3.22-3.25 (d, 1H), 3.84 (s, 3H), 6.10 (s, 1H), 6.94-7.40
(m, 8H);

13

C-NMR (CDCl3, 125.66 MHz) δ 20.16, 26.16, 28.19, 34.31, 35.82,

43.91, 55.48, 56.71, 77.52, 109.47, 114.23, 115.13, 119.72, 124.88, 126.51,
133.11, 136.13, 137.47, 150.93, 152.99, 158.40; IR (NaCl, thin film) νmax (cm-1):
3365 (OH), 2930, 2850, 1610, 1517, 1250, 835; HRMS (ESI-RTOF) m/z: [M+H]+
Calcd for C25H29N2O2S, 421.1944; found 421.1907.
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2.8.5 Non-steroidal glucocorticoid 1H-NMR and 13C-NMR spectra
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2.8.6 Non-steroidal glucocorticoid 2D/3D representations of ligand-receptor
interactions
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2.8.7 Non-steroidal glucocorticoid tables of ligand orientations in 5NFP
pocket
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2.8.8 Non-steroidal glucocorticoid EICs and LCMS method for analysis of
crude product 13ag
An LCMS analysis of the crude product of the reaction of 12ag with 10
equivalents of MeLi to determine the relative %-conversion of ketone 12ag to 3°
OH 13ag. This was done to verify that under experimental conditions product
13ag was not being produced from residual ketone 12ag that was produced as a
byproduct from the previous reaction to make compound 11 analogues. 10 µL of
a 50 µM solution of crude product 13ag was injected onto an analytical column
and subjected to the chromatographic method described below.
EIC – [M+H]+ 12ag

LC Column: Synergi™ 2.5 µm Hydro-RP 100Å (100 x 2.0 mm) held at 40
°C
Mobile phase A (%C) – 0.1% formic acid in H2O
Mobile phase B (%B) – 0.1% formic acid in ACN
Flowrate – 300 µL/min
MS Parameters: Scan mode – Full scan; Ionization mode – positive; AGC
target – 3.0x106 ions; Max IT – 200 ms; Resolution – 140,000; Scan range
– 150-500 m/z

209
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Mass spectrum under EIC of 12ag
[M+H]+ calc’d for C23H28FN2O+ = 367.2180 m/z; found – 367.2179 m/z; Δppm = 0.27
Product12ag_13ag01_180628151209 #1225-1241 RT: 12.50-12.65 AV: 17 NL: 8.71E8
T: FTMS + p ESI Full ms [150.0000-500.0000]
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EIC – [M+H]+ 13ag
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Product12ag_13ag01_180628151209 #1328 RT: 13.48 AV: 1 NL: 1.17E7
T: FTMS + p ESI Full ms [150.0000-500.0000]
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Far zoomed-in mass spectrum under 13ag EIC
[M+H]+ calc’d for C24H32FN2O+ = 383.2493 m/z; found – 383.2494 m/z; Δppm =
0.21
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Relative abundance of 13ag to 12ag = 1.55x109 ions 12ag: 5.5x104 ions 13ag =
~ 0.005 % conversion, without considering differences in ionization efficiencies
between 12ag and 13ag.
Product12ag_13ag01_180628151209 #1328 RT: 13.48 AV: 1 NL: 1.63E5
T: FTMS + p ESI Full ms [150.0000-500.0000]
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2.8.9 Steroidal glucocorticoid 1H-NMR and 13C-NMR spectra
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2.8.10 Synthetic glucocorticoid bioassay data
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CONCLUSION

254

The work represented in the two chapters within the document display an
interdisciplinary approach to solving real life issues that humans are dealing with
today. Humans created the issue of dichloromethane byproducts ending up in the
environment and causing drastic effects on the ecosystem and human health.
The experiments that were done on the anaerobic bacteria give real hope that
bioremediation of the toxic byproduct in the environment is very much possible.
On the front of the side effects caused by the long term use of glucocorticoids,
the molecules synthesized offer optimism that a dissociated steroid will be
available on the drug market in the near future. Much progress has been made at
expanding the literature on what we know about glucocorticoids, their structureactivity relationship with the glucocorticoid receptor and reducing the harmful
side-effects of the drugs.
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